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Abstract 
Chromatin is a macromolecular complex predominantly comprising DNA, histones and RNA. 
Its methylation is highly conserved throughout phylogeny as it provides an instructive 
template that helps coordinate context dependent access for gene expression, DNA repair and 
DNA replication. Dynamic changes in chromatin methylation are central to cell fate 
determination and normal development of the organism. Consequently, inherited or acquired 
mutations in the major epigenetic protagonists that regulate methylation of DNA, RNA and/or 
histone proteins are commonly observed in developmental disorders, ageing and cancer. This 
has provided the impetus for the clinical development of epigenetic therapies aimed to reset 
the methylation imbalance observed in these conditions. In this review we discuss the key 
principles of chromatin methylation and focus on how this fundamental biological process is 
corrupted in cancer. We discuss methylation-based cancer therapies and provide a 
perspective on the emerging data from early phase clinical trials therapies that target 
regulators of DNA and histone methylation. We also highlight promising future strategies, 
including monitoring chromatin methylation for diagnostic purposes and combination 
epigenetic therapy strategies that may improve immune surveillance in cancer and increase 
the efficacy of conventional and targeted anti-cancer drugs.   
 
 
Introduction 
The control and adaptability of virtually all biological processes involve post-synthesis 
chemical modification of macromolecules such as DNA, RNA and proteins. One of the most 
abundant modifications, methylation, is widespread throughout all kingdoms of life and 
involves an alkylation reaction where a methyl group replaces a hydrogen atom. Methylation 
is catalysed by methyltransferase enzymes, all of which utilise S-adenosylmethionine (SAM) 
as the methyl donor (Figure 1A).  These methylation “writers” regulate the function and 
activity of three classes of fundamental molecules: DNA, RNA and proteins. They co-operate 
with dedicated “erasers” and “readers” – the protein machinery that removes or recognizes 
these methylation marks. The importance of the various methylation pathways is highlighted 
by the fact that their dysregulation is linked to many diseases1-5. 
 
DNA methylation occurs predominantly at palindromic CpG dinucleotides where a methyl 
group is added to the 5' position of the cytosine pyrimidine ring to generate 5-methylcytosine 
(5mC) (Figure 1B). It also occurs, albeit more rarely, in non-CpG contexts. Three enzymes, 
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DNA methyltransferase (DNMT) 1, 3A and 3B, perform and maintain the patterns of genomic 
methylation (Figure 1B)2. CpGs can undergo further oxidation of the 5-methyl group, 
catalysed by the ten-eleven translocation (TET) family of dioxygenases, to 5-hydroxymethyl 
(5hmC), 5-formyl (5fC), or 5-carboxyl (5caC) forms, which has been proposed as the initial 
step of active DNA demethylation in mammals (Figure 1B)6. More recently, 6-
methyladenosine (m6A) was also identified in mammalian genomes, although its 
physiological consequence remains unclear7,8. For a more detailed discussion of DNA 
methylation please refer to xxx et al in this issue. 
 
RNA methylation constitutes most of the known RNA modifications (over 70 types of RNA 
methylation have so far been identified), their biological and molecular functions remain 
largely unknown (Figure 1C). Indeed, until recently the vast majority of modifications had 
been ascribed only to ribosomal and/or tRNAs due to substrate abundance. However, 
pioneering research is now revealing that all classes of RNA are methylated (for examples see 
REF. 9-13). Furthermore, demethylation at specific sites is possible, at least for m6A (Figure 
1C)14,15. The functional role of RNA methylation in development and disease is an exciting and 
rapidly moving field and will be reviewed in detail by xx et al in this issue.  
 
Protein methylation mainly occurs on the side chains of lysines and arginines (Figure 1D), but 
methylation of histidine, carboxyl methylation of aspartate, glutamate, or carboxyl-terminal 
residues (leucine and isoprenylcysteine) also occur in mammals16. However, histone 
methylation will be a major focus of this review and we will primarily focus on the 
involvement of lysine and arginine methylation pathways in disease (Figure 1E). Lysine 
residues on histones may be mono-, di- or tri-methylated (me1, me2, me3 respectively), 
whereas arginines may be mono-, symmetrically or asymmetrically di-methylated (me1, 
me2s, me2as respectively) (Figure 1D)17. Unlike acetylation and phosphorylation, histone 
methylation does not alter the charge of the histone protein. Arginine methyltransferases, the 
PRMTs, are structurally related, as are the histone lysine methyltransferases, virtually all of 
which contain a conserved SET domain [G] possessing enzymatic activity. One exception to 
this generality is DOT1L, which methylates H3K79 in eukaryotic genomes. A more detailed 
description of histone modification sites and the relevant enzymes can be found in Figure 1E 
and REF. 17.  
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During the methylation reaction, SAM is converted to S-adenosylhomocysteine (SAH) (Figure 
1A), which actually inhibits methyltransferase activity18. Thus, methyltransferases are 
susceptible to events that alter the intracellular SAM/SAH ratio. Interestingly, raising the 
levels of SAM has been shown to repress proto-oncogenes via CpG methylation of their 
promoters19. Additional methylation pathway complexity exists because certain enzymes 
methylate multiple classes of macromolecule. For instance, human nucleolar protein 1 (NOP1) 
catalyses 2'-O-methylation of rRNA as well as methylation of glutamine 105 in histone H2A20. 
In addition, DNMT2 is structurally related to the DNMTs described above, yet it possesses 
only weak DNA methylation activity but catalyses 5-methylcytosine in tRNA very efficiently21. 
 
Until relatively recently, the methyl groups on DNA, RNA and proteins were generally 
considered to be highly stable modifications22. However, identification of specific demethylase 
enzymes (Figure 1) has indicated a more dynamic state of methylation, consistent with 
regulatory and functional roles17. As discussed below, this dynamic behaviour provided the 
rationale for therapeutic intervention. 
  
In this review, we discuss the cellular functions of DNA, RNA and histone methylation, and the 
changes observed in these dynamic marks during normal ageing. We also highlight our 
current knowledge on how mutations in the various writers, readers and erasers of chromatin 
methylation contribute to cancer and why drugs that alter their function may be important to 
treat various malignancies. Early clinical trial data with these drugs are beginning to emerge 
and we provide a perspective on these data and emphasise the key knowledge gained 
regarding the safety and efficacy of this exciting new class of drugs. Finally, we highlight 
promising future strategies for monitoring dynamic changes in chromatin methylation for 
diagnostic and prognostic purposes and discuss potential new avenues whereby manipulating 
chromatin methylation in combination with established anti-cancer drugs may improve the 
clinical utility of epigenetic therapies.  
 
[H1] The cellular functions of methylation  
Important clues to the functions of particular DNA, RNA or histone methylation marks can be 
gained from knowledge of their cellular and intramolecular localizations. Thus, much effort 
has been expended in mapping the modified sites using various biochemical (e.g. chromatin 
immunoprecipitations) and biophysical techniques (e.g. mass spectroscopy), which together 
have revealed detailed genetic, epigenetic and epitranscriptomic methylation profiles. 
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CpG DNA methylation is widespread in mammalian genomes, with around 70% of sites being 
methylated. The exception to this are CpG-rich regions (CpG islands) within the promoters of 
active genes, which are characteristically unmethylated23. CpG DNA methylation represents a 
fundamental mechanism of stable repression underlying processes such as X chromosome 
inactivation [G] and gene imprinting [G]23. It is significantly enriched in heterochromatic 
regions and many inactive gene promoters. Active genes can also harbour methylated CpGs 
within their transcribed regions, where they act to regulate mRNA alternative splicing by 
recruiting methyl-CpG-binding protein 2 (MECP2)24. Notably, many tumour suppressor genes 
are silenced by DNA methylation in cancer23. Mammalian genomes mainly consist of 
repetitive elements and although many are methylated25, their biological significance is 
uncertain. Nevertheless, hypomethylation of these elements is observed in cancer cells26,27 
and this can lead to activation and transposition of the endogenous retroviral sequences 
thereby promoting genetic instability and tumour development1 (Figure 2). 
 
Regarding histone methylation, no strict rule governs its distribution in chromatin (detailed 
in REF. 17 & 28). In loosely packed euchromatin, certain methylations such as H3K4me3 are 
present in active promoters, whereas H3K36me3 is present within actively transcribed 
regions where it preferentially mark exons but is present at lower levels in those that are 
alternatively spliced29. Others, such as H3R17me2as, mark the promoters of active hormone-
regulated genes. Active genes are also marked by H3K79me, but this methylation is also 
linked to many other processes including DNA damage response and heterochromatin 
formation (detailed in REF. 30 & 31). Specific functional regions of the genome, such as 
enhancers and origins of replication, are also marked by specific histone methylations, in 
these cases H3K4me1 and H3K36me1 respectively. Histone methylation in tightly packed 
heterochromatin depends on the subtype; facultative heterochromatin contains genes that 
are differentially expressed during development and/or differentiation and which then 
become silenced. It is characterized by an abundance of the repressive mark H3K27me3, as 
found on the inactive X-chromosome in mammalian female cells, whereas constitutive 
heterochromatin is particularly enriched with the inactive marks H3K9me2 and 
H3K9me317,32. Finally, certain developmental genes possess so-called ‘bivalent’ domains that 
contain both active H3K4me3 and inactive H3K27me3 marks. This ‘poised’ state is thought to 
allow them to rapidly respond to differentiation cues33.  
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Histone methylation predominantly functions via direct recruitment or inhibition of histone 
binding proteins. For example, H3K4me3 specifically recruits activatory proteins, such as 
inhibitor of growth (ING) proteins, to gene promoters whilst inhibiting binding of repressors 
such as the nucleosome remodeling and deacetylase (NuRD) complex17,28. In mammalian 
heterochromatin, H3K9me2/3 is specifically bound by the chromodomain [G] of 
heterochromatin protein 1 beta (HP1β), a protein important for the higher architecture of 
heterochromatin17,28 (Figure 2). Methylation such as H4K20me also underpins genomic 
integrity34. 
 
Although it is undeniable that histone modifications robustly modulate key cellular processes 
and there is compelling evidence for the role of histone methylation in DNA processes, as 
outlined above, it is difficult to formally prove a direct causative role of any histone 
modification in mammalian cells (see REF. 35 for discussion). This situation is further 
compounded by (i) most histone modifying enzymes also methylating non-histone substrates, 
such as the tumour suppressor p53 protein36, and (ii) some methyltransferases methylating 
multiple classes of macromolecule20, as described above. In the case of RNA methylation, the 
situation is even more confounded because the modification can occur post-
transcriptionally37, or co-transcriptionally9. Furthermore, unlike histone methylation, some 
methylations of RNA (e.g. m7G) can directly affect local secondary structures by interfering 
with non-canonical base pairing. Other methylations may act as binding platforms for specific 
binding proteins, as exemplified by m6A, which is bound by YTH-domain proteins38. Utilizing 
these mechanisms, RNA methylation can directly affect processing, stability, translation and 
localization39. The effect may even be trans-acting, as exemplified by m6A in Xist RNA that is 
required for it to mediate transcriptional repression40. 
 
Thus, methylation is widespread throughout the genome and epitranscriptome. This creates 
an obvious and huge potential for crosstalk between different methylation pathways. This is 
exemplified in histones, where crosstalk occurs between methylations, not only within the 
same histone but also between modifications in different histones17,28. There can also be 
cooperation between methylation of histones and DNA. For instance, the RING E3 ubiquitin 
ligase Ubiquitin Like With PHD And Ring Finger Domains 1 (UHRF1) binds to nucleosomes 
harbouring H3K9me3, and this is significantly enhanced by CpG methylation of the 
nucleosomal DNA41. Furthermore, the ubiquitin-like domain within the ligase promotes 
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ubiquitination of histone H3, which recruits DNMT1 to newly replicated chromatin to ensure 
the inheritance of DNA methylation42.  
 
As discussed above, distinct general methylation patterns are found in heterochromatin and 
euchromatin domains. In fact, there are well-defined regions of demarcation, so-called 
'boundary elements’, between heterochromatin and euchromatin suggesting that 
methylations may be involved in establishing and/or maintaining the higher order topological 
structures of the genome. Indeed, specific factors such as CCCTC-binding factor (CTCF), which 
play a role in maintaining boundaries between distinct chromatin regions, bind to DNA in a 
methylation-dependent manner43,44. CpG methylation prevents CTCF binding, suggesting a 
role for DNA methylation in regulating these sites (Figure 2). 
 
[H1]  Methylation in ageing and cancer  
Although the primary focus of this review is on the role of chromatin methylation in cancer, it 
is important to emphasise that methylation of DNA, RNA and histones has also been widely 
implicated in developmental diseases, non-malignant acquired diseases such as autoimmunity 
and ageing. Overall, the key principles of the methylation pathways, in terms of location and 
regulation of DNA templated processes, are highly conserved throughout mammals. Indeed, 
their importance is underscored by the fact that disruption of these processes, through 
inherited or acquired mutations in the main protagonists, results in embryonic lethality or 
can produce severe disease states1-5. Mutations related to developmental diseases have been 
well described in the literature and the major mutational targets are listed in Supplementary 
Table 1. 
 
As a cell ages, the methylation landscape changes dynamically (Figure 2). Early studies 
suggested that global DNA hypomethylation is a hallmark of aging; however, recent work has 
highlighted that  loss of DNA methylation occurs primarily in repetitive regions of the genome 
that correlate with constitutive heterochromatin, whilst hypermethylation primarily occurs at 
promoter CpGs45,46. As discussed above, in normal tissues repetitive elements are maintained 
in heterochromatin and highly methylated to prevent their transcription. Ageing is 
accompanied by selective loss and reorganization of heterochromatin and upregulation of 
transcripts from repeat regions, in particular retrotransposable elements47, which are 
associated with DNA double strand breaks48,49 and can negatively impact on genome stability 
and disease50. In contrast, a stable epigenome is reported to contribute to longevity and 
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cancer resistance51. In addition, locus-specific DNA hypermethylation has been associated 
with ageing blood and tissues52,53 and appears to be conserved between mice, monkeys and 
humans54. DNA methylation tends to increase with age at some CpG islands, particularly at 
polycomb target genes55,56 and at promoters of tumour suppressor genes57. The sum of these 
changes in DNA methylation likely lead to an age-related transcriptional programme53. In line 
with this, a number of DNA methylation clocks have been described (discussed in 58) and 
genome-wide DNA methylation has been shown to serve as a reliable estimator of age59 and 
can predict mortality60 and lifespan61,62 in model organisms.  
 
Histone methylation changes with ageing are also context specific and there are conflicting 
data from different ageing models (detailed in REF. 63 and 64). A gain of novel bivalent 
domains is observed in ageing cells65,66 (Figure 2), and increased levels of the 
heterochromatin-associated proteins, including histone H2A variant macroH2A (associated 
with gene repression67) and HP1β, were observed in tissues from old versus young mice and 
primates68,69. A general loss of histones and redistribution of methylation marks has also been 
observed in yeast and human fibroblasts70,71, suggesting this is an evolutionarily conserved 
mechanism that regulates replicative lifespan [G], but it remains unclear if replicative 
senescence also occurs in mammalian cells in vivo.  
 
In addition to changes in DNA and histone methylation, certain mRNAs are less m6A 
methylated in old versus young human blood cells72. Thus, biological methylations exist in 
flux, responding to various pathologies and natural processes such as ageing. It is the 
existence of such dynamic equilibria that underpins the rationale to therapeutically target 
these pathways in the hope that pathological perturbation of the methylome can be reversed. 
 
Advancing age sets the platform for the development of a range of acquired age-associated co-
morbidities that ultimately shorten the life span of the organism, one of the best studied of 
which is cancer. Of note, the same changes documented in ageing cells, such as demethylation 
of retrotransposons and satellite DNA and high levels of their transcription, are also observed 
in human cancer73-75. In recent years, we have begun to gain fascinating insights into the 
origins of cancers, which are derived from clonal populations of cells, bearing dysregulated 
chromatin. An excellent example of this is Age Related Clonal Hematopoiesis (ARCH)61. 
Several laboratories have independently demonstrated that in more than 10% of adults aged 
60 years or older, steady state haematopoiesis (> 5 x 1011 blood cells generated each day) 
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occurs from a restricted number of clonal haematopoietic stem and progenitor cells 
harbouring somatic mutations that confer a clonal advantage. Strikingly, ARCH is associated 
with an increased risk of a subsequent haematological malignancy and with an almost two-
fold increased risk of cardiovascular mortality76-78. Mutations in genes encoding DNMT3A, 
TET2 (Supplementary Table 1) and additional sex-combs like 1 (ASXL1), which regulate DNA 
and histone methylation, account for greater than 70% of cases of ARCH76-78. Remarkably, 
these findings in patients79 could have been largely predicted from mouse models where 
these genes have been conditionally deleted in haematopoietic tissues. Haematopoietic stem 
cells (HSC) from these mice show an increased self-renewal capacity, allowing them to 
outcompete non-mutated HSC and clonally expand80-85. The prognostic significance of 
diseases such as acute myeloid leukaemia (AML), arising from pre-existing ARCH, is yet to be 
fully determined. However, the presence of clonal haematopoiesis was reported to negatively 
impact clinical outcomes in patients receiving treatment for non-haematological cancers86. 
Clonal haematopoiesis does not just influence cancer development and therapeutic response 
but is also a major risk factor for atherosclerotic disease, which is another feature of 
ageing87,88. There remains much to be learnt about the global changes in chromatin 
methylation in conditions such as ARCH, and how this has such a profound influence on the 
cancer and cardiovascular disease. Whilst there is compelling evidence correlating ARCH with 
a range of pathologies frequently observed in advanced age, if we are to develop strategies to 
alter the natural history of this process it is imperative that we understand the molecular 
aetiology behind these associations.  
 
[H2] Methylation deregulation in cancer 
Global and regional changes to DNA and histone methylation are a seminal feature of cancer 
cells (Figure 2). A major finding from the cancer genome efforts has been that pervasive 
mutations occur in a range of enzymes that methylate and de-methylate DNA and histones1,89. 
Nevertheless, the diverse range of molecular mechanisms employed by cancer cells to 
dramatically alter chromatin methylation patterns was relatively unexpected. These 
mechanisms include mutations in metabolic enzymes, resulting in production of 
oncometabolites [G] that essentially poison the iron-dependent dioxygenases that regulate 
histone and DNA demethylation, and somatic mutations in the core histone genes that lead to 
a global loss of the histone modifications (Figure 3).  
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D-2-hydroxyglutarate (D2HG) is one such oncometabolite, which inhibits numerous 
demethylases, leading to changes in genomic and transcriptomic methylation profiles as well 
as gene expression and genome topology32,90-92. Oncogenesis has been associated with specific 
mutations in isocitrate dehydrogenases (IDHs), which prevent conversion of isocitrate to α-
ketoglutarate (α-KG) and additionally promote the reduction of α-KG to the structural analog 
D2HG93,94. Both the TET family of proteins involved in DNA demethylation and the Jumonji-C 
domain family of histone demethylases, are examples of iron-dependent dioxygenases whose 
catalytic activity at chromatin is competitively inhibited by elevated levels of D2HG. Mutations 
in IDH1 and IDH2 are mutually exclusive in AML, and IDH1/2 mutations induce cytosine 
hypermethylation and inhibit TET2-mediated 5-hydroxymethylation95,96. This results in 
aberrant DNA cytosine methylation (5mC and 5hmC) patterns, including hypermethylation at 
genes involved in proliferation and differentiation, as well as histone methylation gains. The 
observation that IDH1 and IDH2 mutations can partially phenocopy the loss of TET function 
may explain the mutual exclusivity of these mutations in cancer95,97. This is supported by the 
clustering of DNA methylation profiles of TET2-mutant AML with IDH1- and IDH2-mutant 
cancers, suggesting several common targets.  
 
In addition to TET enzymes, D2HG can inhibit the N6-methyladenosine (m6A) RNA 
demethylase fat mass and obesity associated protein (FTO), another α-KG-dependent 
dioxygenase15. This leads to significantly higher m6A levels in IDH1/2-mutant than in 
IDH1/2-wild-type AML, despite comparable FTO expression90. Although evidence points to an 
oncogenic role of FTO in AML15, a recent study suggested that inhibition of FTO by 
accumulated D2HG may have opposing pro- and anti-tumour effects in both AML and glioma, 
dependent on the mutation status of IDH, and the abundance of FTO and MYC98. 
Deconvoluting the contribution of each enzyme affected by D2HG and understanding what 
role the observed changes in DNA and histone methylation play in initiating and maintaining 
these malignancies is the subject of ongoing research and is likely to influence future 
therapeutic decisions.  
 
One of the best examples of dysregulated histone methylation resulting in changes to gene 
expression and genome integrity is the extensive loss and gain of H3K27me3. This can occur 
through multiple distinct mechanisms, including recurrent gain- or loss-of function mutations 
in enhancer of zeste 2 (EZH2), the primary methyltransferase responsible for this histone 
modification99. More recently, we have also learnt how the catalytic activity of EZH2 can be 
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compromised by so called ‘oncohistones’100 (Figure 3). Around 30% of all paediatric 
glioblastomas contain mutations in histone genes resulting in H3K27M, H3K27I and 
H3G34V/R substitutions (reviewed in REF. 100). Of these, up to 90% of diffuse intrinsic 
pontine gliomas (DIPG) harbour a point mutation in canonical (HIST1H3B (H3.1)) or variant 
(H3F3A (H3.3)) histone H3, resulting in a lysine 27 to methionine (K27M) substitution101-103. 
While these histone genes are associated with distinct DNA mutations (detailed in REF. 104) 
they are maintained throughout the course of the disease, suggesting that they are driver 
mutations, and required for tumour maintenance105. H3K27M mutations in H3.1 or H3.3 are 
mutually exclusive with each other, and with mutations in H3.3 that result in a glycine 34 to 
arginine or valine (G34R/V) substitution. Whilst these tumours are histologically 
indistinguishable, the different histone mutations mark a clinically and epigenetically distinct 
group of glioblastomas. The H3.3G34R/V mutated tumours are found almost exclusively in 
the cerebral hemispheres101,102, whereas H3.1K27M tumours are restricted to an area of the 
brainstem called the pons and H3.3K27M tumours can also be found along the midline of the 
brain106. This striking anatomical restriction is currently unexplained and potentially suggests 
a distinct cell of origin or a cell extrinsic factor, such as the surrounding tumour 
microenvironment that significantly influences the anatomical tropism for these genetically 
distinct tumours. These tumours promote similar global histone modification changes, most 
notably H3K27me2/me3 loss leading to derepression of genes, or redistribution of the active 
mark H3K36me3, together with a general DNA hypomethylation phenotype. Global 
H3K27me3 loss in H3K27M DIPG was initially proposed due to inactivation of polycomb 
repressive complex 2 (PRC2), of which EZH2 is a canonical subunit, via sequestration of EZH2 
to H3K27M107. Despite reports supporting a higher affinity of PRC2 for H3K27M as compared 
with wild-type H3108-110, H3K27M was often inversely correlated with PRC2 occupancy, 
challenging the idea that H3K27M sequesters PRC2 on chromatin111,112. A new model, which 
proposes a dynamic hit-and-run PRC2-H3K27M interaction, may reconcile some of these 
findings113. Several studies have shown that the loss of H3K27 trimethylation leads to major 
gene expression changes that are accompanied by a concomitant gain of acetylation at 
H3K27107,111,114. These findings have encouraged a number of laboratories to explore the 
possibility that epigenetic therapies may reset the imbalance caused by the oncohistone115-119. 
Despite these advances, we are still at the early stages of our understanding about the 
molecular mechanisms by which oncohistones contribute to these anatomically distinct 
malignancies and how they may be therapeutically targeted.  
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[H1] Therapeutically targeting methylation 
A key rationale for targeting epigenetic regulators in cancer lies in manipulating the 
oncogenic transcriptional programme to modulate the expression of genes driving malignant 
progression and in essence reprogramme cancer cells to a more ‘normal’ differentiation state. 
An array of novel compounds targeting the enzymatic domains of methyltransferases that 
‘write’ chromatin methylation, demethylases that ‘erase’ this modification or chromatin 
proteins that have specialised domains that ‘read’, or bind, chromatin methylation have 
entered the preclinical and clinical arena in recent years120. Here we will primarily focus on 
the first-in-class epigenetic therapies that have progressed to evaluation in clinical trials.  
 
[H2] Inhibitors of DNA methyltransferases  
Inhibitors of DNMTs in current clinical use, such as azacytidine (5’-azacytidine) and 
decitabine (5-aza-2’-deoxycytidine), are cytidine analogues that incorporate into replicating 
DNA and covalently bind and sequester active DNMTs, triggering their degradation by the 
proteasome. These inhibitors therefore have broad cellular effects due to indiscriminate 
inhibition of all DNMT-containing complexes, leading to a global loss of DNA methylation121. 
In addition, incorporation of cytidine analogues into RNA and DNA induces DNA damage and 
inhibition of protein synthesis, leading to cytotoxicity at high doses. Lower sub-cytotoxic 
doses have received regulatory approval for the treatment of myelodysplastic syndrome 
(MDS) and AML as agents with demonstrated efficacy for patients unfit for intensive 
chemotherapy122-124. The prolonged time to initial response, which typically occurs around 3 
months from treatment onset125, is consistent with the primary effects of low dose treatment 
being mediated via DNA demethylation and epigenetic reprogramming as opposed to direct 
cytotoxicity126-128. Whilst response rates of up to 60% to azacytidine have been reported in 
MDS125,129, DNMT inhibitors have shown limited clinical efficacy as monotherapy for solid 
tumours. This has been attributed to a number of factors including limited DNA incorporation 
as a consequence of slower cell proliferation in solid tumours, poor cellular uptake and 
metabolic instability. This prompted the development of modified cytidine analogues with 
improved stability and oral bioavailability129. Several of these have shown efficacy in 
preclinical solid tumour models and are currently in clinical trials in a range of malignancies 
(Table 1). Despite their limitations, DNMT inhibitors are the most effective epigenetic therapy 
developed to date and it is hoped that the future development of specific catalytic inhibitors of 
individual DNMT enzymes, or targeting of specific DNMT-containing complexes, may deliver 
more potent and specific anti-tumour effects whilst circumventing the dose-limiting toxicities 
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associated with cytidine analogues. To this end, a reversible non-DNA incorporating selective 
inhibitor of DNMT1 has recently been developed and shown to elicit global reduction in DNA 
methylation and inhibit tumour growth in mouse tumour models130.  
 
[H2] Modulators of histone methylation 
A large number of specific inhibitors of different histone methyltransferases have been 
developed over the last few years (reviewed in 131 and 132). Inhibitors of EZH2, DOT1-like 
histone lysine methyltransferase (DOT1L), protein arginine methyltransferase 1 (PRMT1) and 
5 (PRMT5) have now entered clinical trials with clinical development being most advanced 
for inhibitors of EZH2. EZH2 is the enzymatic component of the core PRC2 complex, whose 
activity is stabilised through binding to suppressor of zeste 12 (SUZ12), embryonic ectoderm 
development (EED) and retinoblastoma binding protein P46 (RbAp46/48)133. EZH2 catalyses 
mono-, di- and tri-methylation of H3K27, which is linked to transcriptional silencing99. 
Although possessing less potent histone methyltransferase activity, the EZH2 homologue 
enhancer of zeste 1 (EZH1) may contribute to H3K27 methylation in specific contexts, 
particularly in the presence of low levels of EZH2134. EZH2 plays a critical role during B-cell 
maturation and is a promising therapeutic target in multiple myeloma, follicular lymphoma 
and diffuse large B-cell lymphoma (DLBCL)135. Around 20-30% of follicular lymphomas and 
germinal centre-DLBCL harbour heterozygous point mutations in specific residues in the 
EZH2 SET domain (Y641, A677, A687), which enhance targeting of di- and mono-methylated, 
rather than unmethylated, H3K27 leading to substantially increased levels of H3K27me3136-
138. An acquired dependence on EZH2 activity is also seen in BRCA1 associated protein 1 
(BAP1)-mutant malignant mesothelioma139 and in tumours with defects in the chromatin 
remodelling switch/sucrose non-fermentable (SWI/SNF) complex140,141, for example 
SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B 
member 1 (SMARCB1 (INI1))-deficient malignant rhabdoid tumours142. The SWI/SNF 
nucleosome remodelling complex antagonises PRC2-mediated gene silencing and has been 
shown to evict polycomb complex components from chromatin143,144. SWI/SNF inactivation is 
synthetic lethal with EZH2 mutations in a range of cancers. Whilst the simplest model 
proposes that SWI/SNF mutations drive transformation through gain of PRC2 function and 
silencing of tumour suppressor genes, non-catalytic activity of EZH2 has also been implicated 
and it has been suggested that combined loss of both SWI/SNF and PRC2 function could 
induce cell death due to global transcriptional dysregulation rather than derepression of 
specific PRC2 targets134,140,142,145. BAP1 is a deubiquitinase targeting histone H2AK119 that 
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opposes polycomb mediated silencing146, however, sensitisation to EZH2 inhibitors following 
BAP1 loss appears to be cell type specific and has been observed in mesothelioma but not 
uveal melanoma139,147. PRC2 can also function as a tumour suppressor and recurrent 
inactivating mutations in EZH2 have been reported in myelodysplastic syndrome and chronic 
myeloproliferative neoplasms148-152. Loss-of-function mutations in other core PRC2 
components EED and SUZ12 are also seen in T-cell acute lymphoblastic leukaemia and 
malignant peripheral nerve sheath tumours153-155. The contrasting function of PRC2 in 
different tumour contexts is thought to reflect the critical role the specific cellular 
transcriptional programme and chromatin environment plays in determining the genes 
targeted by PRC2 and highlights the need for careful monitoring of patients treated with EZH2 
inhibitors156.  
 
Aberrant EZH2 activation is a feature of multiple cancers, including breast cancer, castration-
resistant prostate cancer, small cell lung cancer (SCLC) and neuroblastoma and has been 
linked to oncogenesis and acquisition of stem cell-like transcriptional programmes157-163. 
Although EZH2 upregulation may be a consequence rather than a driver of the malignant 
process in some cancers134, preclinical studies have nevertheless demonstrated EZH2-
dependency in many of these tumour types. Multiple EZH2 inhibitors are currently being 
evaluated in ongoing phase I/II clinical trials in a range of cancers (Table 1). Interim phase I 
results have demonstrated a favourable safety and tolerability profile, with dose-limiting 
toxicities a rare occurrence164-166. Encouragingly in follicular lymphoma, 71% of patients with 
activating EZH2 SET domain mutations responded to EPZ-6438 (Tazemetostat), with 11% of 
patients achieving a complete response166. In contrast, only 33% of the patients without EZH2 
mutations responded and 31% developed progressive disease. Promising clinical results have 
also been reported in BAP1-inactivated malignant mesothelioma, with 51% of patients 
achieving disease control at 12 weeks, which was sustained to 24 weeks in 25%165. Clinical 
responses have also been reported in a small number of patients with SMARCB1-mutant 
tumours164. Overall, given that the majority of trials were conducted in heavily pre-treated 
patients with limited treatment options, it is encouraging that responses to EZH2 inhibitors 
have been seen. The increased response rates in EZH2-mutant tumours mirrors preclinical 
studies and highlights the importance of understanding the mechanisms underlying EZH2 
dependence in order to target treatment to those patients most likely to respond135,167-169. 
This is particularly important given the highly context-dependent function of EZH2, 
underscored by the contrasting oncogenic and tumour suppressive roles of EZH2 in different 
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cancers156.  
 
DOT1L is an H3K79 methyltransferase that is integral to the initiation and maintenance of 
MLL fusion-protein driven leukaemia. In a recently reported phase I study, the DOT1L 
inhibitor EPZ-5676 (Pinometostat) (Table 1) was shown to be well tolerated and induced a 
complete remission in 2 of 51 patients with MLL fusion-protein leukaemia, providing proof of 
concept that targeting DOT1L can impact the progression of this aggressive disease170. 
However, response rates were lower than had been hoped given the critical role of DOT1L in 
preclinical models of MLL fusion driven malignancies. More recently, the arginine 
methyltransferase PRMT5 has been implicated in driving neoplastic growth of multiple 
tumours including B cell lymphoma, multiple myeloma, breast cancer and glioblastoma171-178. 
Preclinical studies employing PRMT5 inhibition provided a rationale for targeting this enzyme 
in both haematological and solid tumours, and on the back of these data specific inhibitors of 
PRMT5 have recently entered early stage clinical trials179. It is currently too early to 
understand where these drugs will have the greatest efficacy and if biomarkers of response 
may emerge from the clinical evaluation.  
 
Similar to the context-dependent function of histone methyltransferases, the dynamic 
association of lysine demethylases with multi-protein complexes governs their stability and 
substrate specificity180. Given its role in promoting growth and inhibiting differentiation in 
AML and SCLC, lysine-specific demethylase 1A (LSD1) has been the primary focus for 
pharmacological targeting in the clinical setting to date132. Small molecule inhibitors of LSD1, 
currently in clinical trials (Table 1), irreversibly inhibit LSD1’s demethylase activity by 
covalently binding the FAD cofactor. Preliminary results from a phase I trial of ORY-1001 
demonstrated an acceptable safety profile and some evidence of clinical efficacy in AML, with 
partial responses in 3 of 14 patients181. Further results are awaited from ongoing trials in 
AML, MDS and SCLC.  
 
[H2] Perspective on early clinical trials 
Given the recent unprecedented interest in chromatin regulators, we now have a suite of 
small molecule inhibitors regulating DNA and histone methylation; however, a key challenge 
facing the field is that our pre-clinical evaluation of these compounds has not equated well to 
the success of these therapies in the clinical arena. Many of the drugs discussed above such as 
DOT1L, LSD1 and EZH2 inhibitors showed remarkable promise in pre-clinical studies, 
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however, their clinical efficacy has been more modest. What does this mean for the field? Far 
from being unproductive, the clinical studies conducted thus far have been invaluable in 
highlighting several important messages. Overall, epigenetic therapies are safe and tolerable; 
when assessing inhibitors to ubiquitously expressed proteins, the importance of this finding 
should not be underestimated. Epigenetic regulators are not directly involved in cell cycle 
progression or apoptosis and consequently most of these therapies do not have an immediate 
cytotoxic effect. Tumour lysis syndrome [G] has rarely been observed and most of these drugs 
have their best clinical response after weeks to months of continuous therapy. Finally, a key 
lesson learnt is that the value of a specific epigenetic therapy, much like the function of most 
epigenetic regulators, will be disease-specific and context-dependent, explaining the relatively 
low complete response rates in most epigenetic therapy trials.  
 
Given the modest outcomes from the early clinical trials, are epigenetic therapies ineffective? 
One could argue that anyone who had expected a single agent epigenetic therapy to be a 
panacea for multiply relapsed and refractory cancer had not fully appreciated the primary 
function of this class of proteins and/or the vast adaptive potential of cancer cells. In many 
ways it is not surprising that single agent epigenetic therapies have only had a modest 
response in the clinical setting. In somatic tissues, epigenetic regulators function primarily to 
nuance access to the DNA template for DNA repair and replication and gene expression. The 
ambition for many of these drugs had been to target an essential dependency required to 
sustain a malignant transcription programme. However, targeting epigenetic regulators 
inevitably induces global changes in chromatin architecture and the cellular transcriptional 
programme, therefore the ability to link therapeutic effects to regulation of specific genes 
across different tumours is likely to be the exception rather than the rule. It is also important 
to appreciate that many of the enzymes targeted, particularly lysine and arginine 
methyltransferases, have non-histone substrates and the significance of this to the 
therapeutic and toxic effects of targeting these enzymes is yet to be fully elucidated182,183.  
 
It is too early to pass judgement on the role of epigenetic therapies in cancer management. 
There remains much to be learnt about how best to leverage these small molecules in the 
clinical setting and a better understanding of mechanisms of resistance to these drugs is 
needed. A consistent theme is that cancer cells adapt to survive the therapeutic challenge by 
finding an alternative mechanism to sustain the malignant gene expression programme in the 
presence of the epigenetic therapy. For instance, whilst several epigenetic therapies targeting 
 17
the prototypical oncogene MYC through transcriptional repression generated much 
excitement, it is now clear that this is only transiently effective as cancer cells evolve multiple 
adaptive responses to retain MYC expression184-186. The mechanisms that underpin these 
adaptive responses and render epigenetic therapies ineffective are varied and include 
tumour-intrinsic mechanisms and heterogenous cellular and molecular effects of the drugs187. 
Thus far the tumour-intrinsic mechanisms of resistance appear to be quite different to the 
paradigm of acquired resistance reported for other targeted therapies such as kinase 
inhibitors188. For example, there have been few descriptions of classical ‘gate-keeper’ 
mutations [G] in the epigenetic writer, reader and eraser domains targeted by epigenetic 
drugs. These observations suggest that mutations in the functional domain most likely result 
in sufficient functional compromise to the epigenetic regulator and probably phenocopy the 
effects of the drug, consequentially providing no selective advantage to the cancer cell. Pre-
clinical modelling of resistance mechanisms has shown that resistance to these therapies 
largely emerge through cellular reprogramming and transcriptional plasticity184-186.  
 
The possibility that epigenetic therapies provide a fixed barrier that enforces an adaptive 
transcriptional response from cancer cells, presents a unique opportunity. Could they be used 
to homogenise intra-tumour heterogeneity? If the choices of cancer cell adaptation to any 
therapy are thought of as a large roundabout with several different exits representing 
alternative routes, including genetic evolution, divergent transcriptional programmes or 
metabolic pathways, or a phenotypic switch such as epithelial to mesenchymal transition 
(EMT), could epigenetic therapies be used as an instructive pressure to enforce a homogenous 
path to escape? If so, this would create a predictable vulnerability that could be targeted with 
a second drug in combination to achieve maximum therapeutic benefit. It is likely that the 
adaptive response to the same epigenetic therapy will be different in a cell context-dependent 
manner. For this strategy to be effective, a more detailed understanding of the shared routes 
of escape in each cancer will be required.  
 
(H1) Combination and future therapies  
The cornerstone of cancer therapy is effective and rational drug combinations. This paradigm 
is central to the future success of epigenetic therapies. The key issue is how best to combine 
these drugs and with what?  
 
Numerous different combination strategies are currently being pursued in clinical trials, 
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encompassing combination of epigenetic therapies with chemotherapy, targeted therapies 
and immunotherapy (Figure 4 and Table 1). The evidence that cancer cells can escape from 
selective pressure through transcriptional adaptation provides a molecular rationale for 
utilising epigenetic therapy to block or reverse resistance. Furthermore, the potential for 
epigenetic inhibitors to promote tumour immunogenicity has generated excitement about 
combining these drugs with immunotherapy, particularly antibodies targeting T-cell 
inhibitory receptors such as anti-PD-1 and anti-CTLA-4 (Table 1).  The power of these 
immune checkpoint inhibitor therapies to induce sustained remission in patients with 
advanced malignancies has created hope that identifying appropriate therapies to combine 
with these agents will broaden the therapeutic efficacy to encompass more patients and a 
broader range of tumour types.  
 
(H2) Immunotherapy 
The clear dynamic interplay between modulation of epigenome and downstream effects on 
cancer immune surveillance is an emerging area of interest. It is recognised that common 
epigenetic regulators govern both inflammation-induced and oncogenic transcriptional 
programmes189. This is particularly relevant to interactions between tumour and host where, 
in an ideal scenario, targeting the same chromatin regulator would inactivate an oncogenic 
pathway, enhance tumour immunogenicity and modify transcriptional programmes in 
responding immune cells to enhance their anti-tumour function. The concept that modulating 
the host immune response may contribute to the full potency of epigenetic therapies is 
supported by several recent reports and could in part account for the slow temporal kinetics 
of response to these agents190. It has been shown that both DNMT and LSD1 inhibitors induce 
de-repression of endogenous retroviral elements (ERVs) and production of double stranded 
RNA that activates anti-viral sensing pathways triggering tumour type I interferon 
production191-193. This enhanced tumour interferon signalling is further augmented following 
combination of DNMT inhibitors with histone deacetylase (HDAC) inhibitors and in preclinical 
studies these epigenetic agents induced intra-tumoural T-cell infiltration and augmented the 
response to immune checkpoint inhibitors194,195. Chromatin modifiers also have direct 
context-dependent roles in shaping cytokine responses and orchestrating immune cell 
differentiation. For example, inhibiting EZH2 activity can either positively or negatively 
influence tumour-specific immune responses by modulating both tumour immunogenicity 
and the function of infiltrating T-cells, NK-cells and macrophages196. Interestingly, a role for 
RNA methylation in modulation of immune function was recently reported.  Depletion of 
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YTHDF1 (YTH N6-methyladenosine binding protein 1), which binds m6A-modified mRNA, 
enhanced cross-presentation of tumour antigens by dendritic cells. This effect was attributed 
to inhibition of lysosomal protease production and resulted in substantially enhanced CD8+ 
T-cell mediated anti-tumour immunity in YTHDF1 knockout mice197. 
 
(H2) Targeted therapies 
High EZH2 activity plays a key role in the pathogenesis of germinal centre-DLBCL and 
follicular lymphoma though repression of B-cell terminal differentiation genes and provides 
an example of synergism between EZH2 inhibition and therapeutic targeting of essential B-
cell dependencies135. EZH2 inhibition in both EZH2-mutant and wildtype DLBCL increases 
dependence on B cell activation signalling and thus synergises with targeted inhibitors of B-
cell receptor signalling such as Bruton’s Tyrosine Kinase (BTK) inhibitors198. B-cell lymphoma 
6 (BCL6) and EZH2 co-operate to maintain stable silencing of B-cell differentiation genes and 
combination therapy with E2H2 and BCL6 inhibitors more potently inhibits DLBCL growth 
than single agent treatment in preclinical models199. Translocations involving B-cell 
lymphoma 2 (BCL2) are the key pathogenic driver of follicular lymphoma, and BCL2 is 
frequently dysregulated in DLBCL. The antiapoptotic function of BCL2 promotes tumour 
survival and BCL2 inhibitors are currently being evaluated in clinical trials. Combining EZH2 
with BCL2 inhibitors more effectively suppresses the growth of DLBCL xenografts135. 
 
(H2) Chemotherapy 
The potential to epigenetically manipulate and revert chemoresistant transcriptional 
programmes makes combining epigenetic agents with chemotherapy an attractive 
prospect126,160,200. A less explored aspect is the potential for using epigenetic agents to 
augment cytotoxicity by amplifying the DNA-damaging effects of chemotherapy, radiotherapy 
or targeted agents. DNA and histone methylation have a critical role in the response to DNA 
damage and DNA repair pathways. For example, p53-binding protein 1 (53BP1) is recruited 
to the site of DNA double strand breaks (DSBs) and binds to specific post-translationally 
modified histone residues, including H4K20me2, and H3K79me via its tandem Tudor 
domain31,201. Blocking H3K79 methylation by depleting DOT1L inhibits 53BP1 recruitment to 
DSBs202. In yeast, Dot1 promotes DNA repair via homologous recombination and in 
mammalian cells DOT1L depletion leads to defects in DNA repair, enhancing sensitivity to 
DNA damaging agents203,204, and also impairs transcriptional recovery following genotoxic 
stress205. Utilising inhibitors of DOT1L or other epigenetic agents to sensitise cancer cells to 
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DNA damaging agents via dysregulation of DNA repair pathways is an important potential 
future therapeutic avenue. 
 
(H2) Combining epigenetic therapies 
Combinations of two different epigenetic agents are also being explored. Trials combining 
DNMT with HDAC inhibitors have yielded mixed results at the cost of increased toxicity, likely 
attributable to the broad specificities of agents in current clinical use206. Given that epigenetic 
proteins frequently participate in multiple chromatin complexes with diverse functions, an 
important limitation of epigenetic therapies is the broad inhibition of all complexes 
containing the target protein generating potential unwanted adverse effects. An innovative 
strategy to more selectively target an individual epigenetic regulatory complex, is the 
development of inhibitors that concurrently target two epigenetic proteins within the same 
complex. The feasibility of this approach has been demonstrated by the recent development of 
dual inhibitors of LSD1 and HDACs, which provide more effective and sustained inhibition of 
the REST corepressor 1 (CoREST) complex than existing class I HDAC inhibitors, and more 
potently inhibit melanoma proliferation whilst exhibiting less toxicity to normal melanocytes 
and keratinocytes207. Given the ongoing development and rapid expansion of a library of 
agents binding to specific epigenetic reader, writer and eraser domains, the prospect of taking 
an epigenetic complex-focussed approach to the development of targeted therapeutics 
becomes more tangible, allowing more refined targeting of a specific dysregulated process 
whilst limiting off-target effects. 
 
[H1]  New opportunities for therapeutic intervention and monitoring 
The observations that derepression of ERVs can enhance anti-cancer immune surveillance 
through viral mimicry [G] highlight the potential of specifically leveraging the repetitive 
genome for therapeutic gain (Box 1). Another emerging area with boundless opportunities is 
the possibility of repurposing sequence specific genome editing strategies as therapeutic 
agents (Figure 5A). The feasibility of specifically directing either components of the DNA or 
histone methylation machinery for locus specific gene regulation in human cells ex vivo has 
already been established208. Similarly, it has recently been demonstrated that epigenetic 
therapies can also be localised specifically within the genome using compounds coupled to 
catalytically deficient Cas9, which functions as a synthetic courier209. These tools may allow us 
to effectively activate or silence specific genes or large stretches of chromatin, and to 
specifically alter chromatin topology, replication timing and DNA repair. The application of 
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these strategies to alter disease states in pre-clinical models has yet to be explored and 
transition into clinical approaches will require significant innovation. However, with future 
advances in medicinal chemistry coupled to novel delivery modalities these strategies may 
soon enable us to take precision medicine to a new frontier. 
 
The non-random nature of methylome profiles also suggests a common mechanism, or 
common cell of origin for distinct tumour subtypes. Consistent with this, genome-wide 
mapping of DNA methylation changes has proven useful for classification into prognostic 
subgroups95,102 and for the development of clinically applicable assays in AML210. DNA 
methylation also poses several advantages as a biomarker for cancer diagnosis, including 
early and frequent occurrence of DNA methylation changes in cancer and cell-type specificity.  
DNA methylation is stable in fixed samples and can be easily detected using well-established 
techniques in a range of bodily fluids (Figure 5B). Despite this, publication of close to 200 
biomarkers has yielded only 14 commercially available DNA methylation-based biomarker 
assays designed to measure the methylation of only 13 genes (for a recent review see REF. 
211), and only one of these is used to guide treatment decisions212. There is currently a great 
interest in developing non-invasive methods to monitor dynamic changes in mutation status 
and DNA methylation, for diagnosis and prognosis. The potential clinical application of this 
approach has also recently been highlighted213. Similarly, global changes in 5hmC can also be 
broadly used as a diagnostic biomarker for cancers, and development of protocols for 
detecting 5hmC are of great interest. 
 
[H1] Conclusions and outlook 
The last decade has seen a great convergence of what were previously largely disparate fields 
of research in genomics, epigenetics and chemistry. The heroic efforts in genomics to 
document all the recurrent mutations that underpin various developmental disorders and 
cancers have reinforced the central role of chromatin regulators in these diseases. 
Concurrently, decades of careful biochemistry, cell and molecular biology by chromatin 
biologists have provided invaluable insights into the molecular function of these epigenetic 
regulators. These insights have highlighted the highly dynamic nature of the epigenome and 
provided the molecular rationale for therapeutically targeting these proteins. This challenge 
has been widely embraced by medicinal chemists in academia and the pharmaceutical 
industry. Together, they have produced an unprecedented array of small molecules that target 
proteins responsible for writing, reading or erasing methylation on DNA and histone proteins. 
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Several of these epigenetic therapies have rapidly progressed into early phase clinical trials, 
which have been invaluable to establish the safety of many of these compounds and highlight 
that even as single agents in relapsed and refractory cancers, they show efficacy.  
 
The platform for cross-disciplinary progress has now been established. It provides a unique 
opportunity to make dramatic inroads into the understanding and management of various 
human diseases. The success of this ambition rests on how we tackle the next frontier of 
challenges. Here we see several opportunities; our understanding of the non-coding genome, 
particularly the transposable elements, is still rudimentary. Investigating the regulation of the 
largest fraction of our genome and the role it plays in normal development and pathological 
processes such as cancer may yield new opportunities for therapeutic intervention. A further 
opportunity lies in finding innovative methods to use the knowledge gained over the last 
decade to guide diagnosis and management in everyday clinical practice. Recent efforts to use 
the highly annotated cancer genome to monitor response and resistance to cancer 
therapies214,215 raises the possibility that cancer-specific DNA and RNA modifications may 
similarly prove effective. Finally, and arguably the most important opportunity, is identifying 
how best to integrate epigenetic therapies into routine clinical management. The future 
clearly involves combination strategies, however, given the context-dependent function of 
epigenetic regulators, it is important to carefully establish the best evidence for combination 
drug regimens involving an epigenetic therapy. This is not an insignificant task as all animal 
models of cancer have significant limitations. Genetically engineered mouse models fail to 
recapitulate the intratumour heterogeneity inherent in human cancer and patient derived 
xenograft models also have major limitations in clonal representation and lack an effective 
immune system, which as discussed above, appears to be central to the efficacy of many 
epigenetic therapies. Therefore, it is important to acknowledge and accept these limitations 
and not be guided solely by pre-clinical evidence in imperfect animal models of cancer. A 
detailed understanding of the molecular mechanism that may provide therapeutic benefit 
may be equally, if not more, valuable than empirical pre-clinical efficacy studies. Despite these 
challenges, there is much to be optimistic about for the future of epigenetic therapies. The 
multidisciplinary collaborative approach in recent years involving geneticists, biochemists, 
medicinal chemists, cell biologists and clinicians has yielded an enormous amount of new 
knowledge about the fundamental role of epigenetic regulators in diseases associated with 
advanced age including cancer. Continued collaborative momentum will likely see their 
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efforts make significant differences in the altering the natural history of these disorders in the 
very near future.    
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Box 1. Exploiting the non-coding genome for therapeutic benefit 
Transposable elements constitute the largest fraction of the human genome and methylation 
of DNA and histones plays an integral role in their regulation. Although evolutionarily diverse, 
these elements have a fundamental role in development and disease216. Transposons can be 
highly cell lineage specific and can regulate tissue gene expression programmes through a 
number of mechanisms involving the active promotion or repression of transcriptional 
activity. These elements have been proposed to be critical for establishing the chromatin 
environment that facilitates cellular plasticity, a feature not just required for normal 
development but often a central component of oncogenesis. It has been estimated that up to 
30% of transcripts for some tissues can originate in repetitive elements, highlighting the 
major influence these elements have on tissue specific gene expression217. Many of these 
transposable elements have a conserved regulatory structure, such as long terminal repeat 
(LTR) elements, which provide a promoter at the 5’ end, and transcriptional termination and 
polyadenylation signals at the 3’ end of some retrotransposons. Consequently evolutionary 
pressure has likely evolved distinct mechanisms to tightly control the influence of 
transposons. For instance, it has recently become apparent that vertebrate specific chromatin 
complexes such as the HUSH complex can be major regulators of the LINE-1 family of 
retrotransposons218,219. The largest fraction of our genome likely holds many intriguing 
possibilities and as our knowledge of this area expands, some of these transposon families 
may be amenable to therapeutic manipulation with epigenetic drugs to effectively manage 
diseases such as cancer.  
 
Figure legends.  
Figure 1: Methylation of DNA, RNA and histones. A. Conversion of S-adenosyl methionine 
(SAM) to S-adenosyl homocysteine (SAH) occurs during a methylation reaction. B. DNA 
methylation: Formation of 5-methylcytidine (5mC) by DNA methyltransferase (DNMT) 
enzymes. Further oxidation steps catalysed by Ten-Eleven Translocation (TET) enzymes and 
potential steps of demethylation are indicated by dashed arrows. The lower cartoon depicts 
CpG methylation by DNMT enzymes on a DNA duplex. DNMT1 preferentially methylates 
hemimethylated CpG sites and maintains methylation after cell division, whereas DNMT3A 
and DNMT3B have an equal preference for unmethylated and hemimethylated sites and they 
are responsible for de novo methylation at the non-CpG sites. Methylation of adenine is shown 
for completion although the enzyme responsible for its methylation (m6A) is unknown. C. 
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RNA methylation: Two examples of RNA modifications are shown (m6A and m7G).  The RNA 
cartoon shows methyltransferases and a demethylase, together with their target nucleotide 
(A, G, C or U) and methylated product (in parenthesis). The cartoon represents a generic RNA 
structure and the exact sites shown are for illustrative purposes only. D. Lysine and arginine 
methylation: Lysine methyltransferases (KMTs) methylate lysines and demethylases (KDMs) 
reverse the methylation. Lysines may be mono-, di- or trimethylated (Kme1, Kme2 or Kme3 
respectively). Arginine methylation is performed by type I and II protein arginine 
methyltransferases (PRMTs) and leads to mono-, di-symmetric or di-asymmetric methylation 
(Rme1, Rme2s or Rme2as respectively). E. Histone methylation: Schematic showing the 
principle sites of methylation within histone H3 and H4 N-terminal tails together with the 
relevant methyltransferases (above) and demethylases (below). 
Methyl groups are shown in green. Methyltransferases are in black text whereas demethylases 
are in red. 
 
Figure 2: Changes in the DNA and histone methylation patterns in cells from young, 
ageing and tumour-bearing individuals. A. In normal cells, CpG methylation is low at 
promoter regions, whereas genic and intergenic regions show high methylation levels220. 
Distal regulatory sequences such as enhancers are commonly marked by low levels of 5-
methylcytidine (5mC) and higher levels of 5-hydroxymethylcytidine (5hmC). A limited 
number of genomic loci gain DNA methylation during ageing and in cancer, in particular CpG 
islands in promoters of tumour suppressor genes (TSGs) and polycomb targets57. Changes in 
enhancer methylation are associated with dysregulated chromatin structure, which is 
normally maintained in distinct regions by boundary factors such as CCCTC-binding factor 
(CTCF) and cohesion. B. In normal tissues, repetitive elements are maintained in 
heterochromatin and highly methylated. Demethylation of retrotransposons and satellites 
and high levels of their transcription are observed in ageing cells47 and in human cancer73-75. 
C. A general loss of  histones is observed in replicative senescence70,71 and ageing cells have an 
altered heterochromatin composition, including high levels of histone H2A variant macroH2A 
and heterochromatin binding protein 1 (HP1β)68,69 Some of these features are also seen in 
cancer cells. D. In ageing cells, a gain of novel bivalent domains is observed, mostly due to 
gains of repressive H3K27me3 marks on regions that were marked by the active histone 
modification H3K4me3 in young cells65,66. Bivalent domains show the lowest DNA 
methylation in normal cells66. During ageing, DNA hypermethylation occurs at bivalent 
chromatin domain promoters55, which is also a key feature of several cancers221-223. This may 
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lead to reduced expression of TSGs. Arrows indicate the strength of gene 
transcription/repression. 
Figure 3: Expression of oncometabolites and oncohistones in cancer lead to changes in 
DNA and histone methylation. A. Mutations in isocitrate dehydrogenase 1 and 2 (IDH1/2) 
promote the reduction of α -ketoglutarate (α-KG) to the oncometabolite D-2-
hydroxyglutarate (D2HG), resulting in inhibition of numerous demethylases. B. Mutations in 
genes encoding histones H1, H2A, H2B and H3 have been reported in cancer (detailed in REF. 
224) which result in expression of oncohistones and marked changes in DNA and histone 
methylation. H3K27M and H3G34R mutations are two examples. The former leads to 
inhibition of polycomb repressive complex 2 (PRC2), while some evidence points to inhibition 
of SET domain containing 2 (SETD2) methyltransferase by H3G34R225. H3.1K27M-, 
H3.3K27M- and H3G34R-mutant glioblastomas are found in distinct parts of the brain 
(indicated by the circles), suggesting difference in cell or origin, or tumour environment. 
Figure 4: Targeting methylation in combination with immunotherapy. Inhibitors of DNA-
methyltransferases (DNMT), enhancer of zeste 2 (EZH2) and lysine-specific demethylase 1A 
(LSD1) are currently being evaluated in clinical trials with immune checkpoint blocking 
antibodies against PD-1, PD-L1 or CTLA-4.  These antibodies block T-cell inhibitory receptors 
promoting activation of CD8+ T-cells, which secrete pro-inflammatory cytokines interferon-γ 
and TNF-α and recognise and kill tumour cells displaying foreign antigens in complex with 
MHC class I. Inhibitors of DNMT, LSD1 and EZH2 can derepress endogenous retroviral 
elements (ERVs) leading to activation of endogenous anti-viral RNA sensing pathways and 
tumour type I interferon production, which acts in an autocrine manner to drive expression of 
interferon stimulated genes (ISGs)191-193,226. Enhanced tumour MHC class I antigen 
presentation in conjunction with increased infiltration of tumours by CD8+ cytotoxic T-cells 
leads to increased tumour killing. EZH2 inhibition has been shown to augment interferon-
induced gene expression in tumour cells227-229. DNMT inhibitors can induce aberrant 
expression of tumour associated antigens such as cancer testis antigens, which provide a 
source of ‘foreign’ MHC-I peptides that may promote the development of tumour-reactive T 
cells. Manipulation of DNA and histone methylation also modulates differentiation and 
effector function of tumour-infiltrating immune cells. Inhibiting EZH2 in T-regulatory cells, 
has been shown to reprogramme them to more pro-inflammatory phenotype and to enhance 
the anti-tumour effects of anti-CTLA-4 therapy230,231. i, inhibitor; IFNAR, interferon-α receptor 
(type I interferon); IFNGR, interferon-γ receptor (type II interferon). 
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Figure 5. New opportunities for therapeutic intervention and monitoring A. Targeted 
drug delivery may be achieved by directing either components of the DNA or histone 
methylation machinery or epigenetic drugs to a specific gene locus, for example by coupling 
them to catalytically deficient (dCas9). B. ‘Liquid biopsies’ are a non-invasive method for 
collecting circulating tumour DNA, for multiple downstream applications, including 
monitoring of DNA methylation. sgRNA, single guide RNA; TF, transcription factor; RNA pol II, 
RNA polymerase II; 5mC, 5-methylcytidine; 5hmC, 5-hydroxymethylcytidine. 
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Table 1. Selected current clinical trials targeting DNA or histone methylation 
Target Inhibitor (Name) Malignancy Phase Year Clinical trial number 
PRC2 Inhibitors     
 
 
 EZH2 EPZ-6438 (Tazemetostat) B cell lymphoma (BCL) with EZH2 mutation II  2018  NCT03456726 
 EZH2 EPZ-6438 (Tazemetostat) DLBCL, Advanced solid tumours I/II 2013  NCT01897571  
 EZH2 EPZ-6438 (Tazemetostat) Rhabdoid tumours, Synovial Sarcoma, SMARCB1- or EZH2-mutant tumours  II  2015  NCT02601950 
 EZH2 EPZ-6438 (Tazemetostat) Paediatric INI1(SMARCB1 negative tumours) or synovial sarcoma I 2015  NCT02601937 
 EZH2 EPZ-6438 (Tazemetostat) Malignant mesothelioma (BAP1 mutant) II  2016  NCT02860286 
 EZH2 EPZ-6438 (Tazemetostat) Recurrent ovarian, primary peritoneal, endometrial carcinoma II 2019  NCT03348631 
 EZH2 SHR2554 Mature lymphoid neoplasms I 2018  NCT03603951 
 EZH2 PF-06821497 Small cell lung cancer (SCLC), CRPC, DLBCL, Follicular Lymphoma I 2018  NCT03460977 
 EZH2 CPI-1205 B-cell lymphoma II  2015  NCT02395601 
 EED MAK683 DLBCL, advanced solid tumours I/II 2016  NCT02900651 
       
DOT1L Inhibitors     
 
 
DOT1L EPZ-5676 (Pinometostat)  Newly diagnosed AML with MLL rearrangement Ib/II 2019  NCT03724084 
DOT1L EPZ-5676 (Pinometostat)  Paediatric AML and ALL with MLL rearrangement Ib 2014  NCT02141828 
       
Arginine Methyltransferase Inhibitors     
 
 
PRMT5 GSK3326595 Advanced solid tumours, Non-Hodgkin Lymphoma I 2016  NCT02783300 
PRMT5 JNJ-64619178 B-cell Non-Hodgkin Lymphoma, advanced solid tumours I 2018  NCT03573310 
       
Demethylase Inhibitors            
LSD1 IMG-7289 Myelofibrosis I 2017  NCT03136185 
LSD1 IMG-7289 ± ATRA AML, Myelodysplastic syndrome I 2016  NCT02842827 
LSD1 SP-2577 (Seclidemstat) Ewing Sarcoma I 2018  NCT03600649 
LSD1 INCB059872 Ewing Sarcoma I 2018  NCT03514407 
LSD1 INCB059872 
AML/MDS, SCLC, myelofibrosis, Ewing 
sarcoma and poorly differentiated 
neuroendocrine tumours 
I/II 2016  NCT02712905 
LSD1 CC-90011 Non-Hodgkin Lymphoma, advanced solid tumours I 2016  NCT02875223 
       
DNA Methyltransferase Inhibitors 
 
DNMT Guadecitabine (SGI-110)  
Paraganglioma, gastrointestinal stromal 
tumours, phaeochromocytoma, hereditary 
leiomyomatosis and renal cell carcinoma 
II 2017  NCT03165721 
DNMT Guadecitabine (SGI-110) Higher risk MDS II 2014  NCT02131597 
DNMT Guadecitabine (SGI-110) AML III 2017  NCT02920008 
DNMT 
5-aza-4'-Thio-2'-
Deoxycytidine (Aza-TdC) 
 
Advanced solid tumours I 2017  NCT03366116 
DNMT 4'-Thio-2'-Deoxycytidine (TdCyd)  Advanced solid tumours I 2015  NCT02423057 
DNMT 5-Fluoro-2-Deoxycytidine (FdCyd) + THU 
Lung, breast, bladder and head and neck 
cancer II 2009  NCT00978250 
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BCL: B cell lymphoma; DLBCL: Diffuse large B cell lymphoma; AML: Acute myeloid leukaemia; ALL: Acute lymphoblastic leukaemia; CMML: 
Chronic myelomonocytic leukaemia; MDS: Myelodysplastic syndrome; MLL: Mixed lineage leukaemia; CRPC: Castration resistant prostate cancer; 
SCLC: Small cell lung cancer; NSCLC: Non-small cell lung cancer; THU: Tetrahydrouridine; IDO: indoleamine 2,3-dioxygenase; ATRA: All-trans 
retinoic acid; R-CHOP: Rituximab, Cyclophosphamide, Vincristine, Doxorubicin, Prednisolone. Trial information from 
https://www.clinicaltrials.gov/ 
 
 
Combinations with immune checkpoint inhibitors 
 
EZH2 + CTLA-4 CPI-1205 + ipilimumab Advanced solid tumours I/II 2017  NCT03525795 
EZH2 + PD-L1 EPZ-6438 (Tazemetostat) + atezolizumab Relapsed or refractory DLBCL I 2014  NCT02220842 
LSD1 + PD-1 INCB059872 + nivolumab SCLC I/II 2016  NCT02712905 
DNMT + PD-1 THU-Decitabine + nivolumab NSCLC II 2016  NCT02664181 
DNMT + PD-1 Azacitidine + pembrolizumab NSCLC II 2015  NCT02546986 
DNMT + PD-1 Decitabine + anti-PD-1 Relapsed or refractory malignancies I/II 2016  NCT02961101 
DNMT + CTLA-4 Decitabine + ipilimumab Relapsed or refractory MDS or AML I 2017  NCT02890329 
DNMT + PD-L1 Guadecitabine (SGI-110)+ atezolizumab MDS, AML, CMML I/II 2016  NCT02935361 
DNMT + PD-1 Azacitidine + pembrolizumab Metastatic melanoma II 2017  NCT02816021 
DNMT + CTLA-4 Guadecitabine (SGI-110) + ipilimumab Metastatic melanoma I 2015  NCT02608437 
DNMT + PD-1 Guadecitabine (SGI-110) + nivolumab Refractory metastatic colorectal cancer I/II 2019  NCT03576963 
DNMT + PD-1 Guadecitabine (SGI-110) + pembrolizumab 
Recurrent ovarian, primary peritoneal or 
fallopian tube cancer II 2016  NCT02901899 
DNMT + PD-L1 Guadecitabine (SGI-110) + durvalumab Advanced renal cancer Ib/II 2017  NCT03308396 
DNMT + PD-L1 Guadecitabine (SGI-110) + durvalumab 
Hepatocellular carcinoma, pancreatic 
adenocarcinoma and cholangiocarcinoma Ib 2018  NCT03257761 
DNMT + PD-L1 Guadecitabine (SGI-110) +  atezolizumab Advanced urothelial carcinoma I/II 2017  NCT03179943 
DNMT + PD-1 Guadecitabine (SGI-110) + pembrolizumab NSCLC, CRPC I 2017  NCT02998567 
DNMT + PD-L1       
or CTLA-4    
Azacitidine + durvalumab 
or tremelimumab Head and neck cancer I/II 2017  NCT03019003 
DNMT, HDAC + 
PD-1 
Azacitidine, Entinostat + 
nivolumab NSCLC II 2013  NCT01928576 
DNMT, HDAC + 
PD-1 
Guadecitabine 
pembrolizumab, and 
mocetinostat 
Advanced NSCLC I 2017  NCT03220477 
DNMT, IDO-1 + 
PD-1 
Azacitidine, epacadostat 
pembrolizumab, Advanced solid tumours I/II 2017  NCT02959437 
LSD1, IDO-1 + 
PD-1 
INCB059872, epacadostat 
pembrolizumab Advanced solid tumours I/II 2017  NCT02959437 
       
Other combinations 
 
PRMT5 + DNMT GSK3326595 + Azacitidine Myelodysplastic syndrome (MDS), CMML, AML I/II 2018  NCT03614728 
LSD1 + DNMT 
 
INCB059872 + ATRA or 
azacitidine AML  I/II 2016  NCT02712905 
LSD1 + DNMT GSK2879552 ± Azacitidine Myelodysplastic syndrome II 2017  NCT02929498 
EZH2 EPZ-6438 (Tazemetostat) + R-CHOP DLBCL I/II 2016  NCT02889523 
DNMT + 
androgen 
receptor 
Decitabine + enzalutamide Castration resistant prostate cancer I/II 2019  NCT03709550 
EZH2 + androgen 
receptor CPI-1205 + enzalutamide Castration resistant prostate cancer I/II 2017  NCT03480646 
DNMT  Azacitidine + chemotherapy AML (newly diagnosed) II 2017  NCT03164057 
DNMT + NEDD8 
activating enzyme Azacitidine + pevonedistat Relapsed refractory MDS or MDS/MPN II 2017  NCT03238248 
DNMT + Poly 
ADP Ribose 
Polymerase 
Decitabine + talazoparib AML I/II 2016  NCT02878785 
       
 30
 
 
References 
 
1. Dawson, M.A. & Kouzarides, T. Cancer epigenetics: from mechanism to therapy. Cell 150, 
12-27 (2012). 
2. Jin, B., Li, Y. & Robertson, K.D. DNA methylation: superior or subordinate in the epigenetic 
hierarchy? Genes Cancer 2, 607-617 (2011). 
3. Luo, C., Hajkova, P. & Ecker, J.R. Dynamic DNA methylation: In the right place at the right 
time. Science 361, 1336-1340 (2018). 
4. Stojkovic, V. & Fujimori, D.G. Mutations in RNA methylating enzymes in disease. Curr Opin 
Chem Biol 41, 20-27 (2017). 
5. Xie, P., Zang, L.Q., Li, X.K. & Shu, Q. An epigenetic view of developmental diseases: new 
targets, new therapies. World J Pediatr 12, 291-297 (2016). 
6. Kohli, R.M. & Zhang, Y. TET enzymes, TDG and the dynamics of DNA demethylation. Nature 
502, 472-479 (2013). 
7. Xiao, C.L., et al. N(6)-Methyladenine DNA Modification in the Human Genome. Mol Cell 71, 
306-318 e307 (2018). 
8. Xie, Q., et al. N(6)-methyladenine DNA Modification in Glioblastoma. Cell 175, 1228-1243 
e1220 (2018). 
9. Barbieri, I., et al. Promoter-bound METTL3 maintains myeloid leukaemia by m(6)A-
dependent translation control. Nature 552, 126-131 (2017). 
10. Berulava, T., Rahmann, S., Rademacher, K., Klein-Hitpass, L. & Horsthemke, B. N6-
adenosine methylation in MiRNAs. PLoS One 10, e0118438 (2015). 
11. Pendleton, K.E., et al. The U6 snRNA m(6)A Methyltransferase METTL16 Regulates SAM 
Synthetase Intron Retention. Cell 169, 824-835 e814 (2017). 
12. Squires, J.E., et al. Widespread occurrence of 5-methylcytosine in human coding and non-
coding RNA. Nucleic Acids Res 40, 5023-5033 (2012). 
13. Xuan, J.J., et al. RMBase v2.0: deciphering the map of RNA modifications from 
epitranscriptome sequencing data. Nucleic Acids Res 46, D327-D334 (2018). 
14. Jia, G., et al. N6-methyladenosine in nuclear RNA is a major substrate of the obesity-
associated FTO. Nat Chem Biol 7, 885-887 (2011). 
15. Li, Z., et al. FTO Plays an Oncogenic Role in Acute Myeloid Leukemia as a N(6)-
Methyladenosine RNA Demethylase. Cancer Cell 31, 127-141 (2017). 
16. Clarke, S. Protein methylation. Curr Opin Cell Biol 5, 977-983 (1993). 
17. Xhemalce, B., Dawson, M.A. & Bannister, A.J. Histone modifications. Epigenetic regulation 
and epigenomics : advances in molecular biology and medicine, (Wiley-Blackwell, 
Weinheim, 2012). 
18. Deguchi, T. & Barchas, J. Inhibition of transmethylations of biogenic amines by S-
adenosylhomocysteine. Enhancement of transmethylation by adenosylhomocysteinase. J 
Biol Chem 246, 3175-3181 (1971). 
19. Wang, Y., Sun, Z. & Szyf, M. S-adenosyl-methionine (SAM) alters the transcriptome and 
methylome and specifically blocks growth and invasiveness of liver cancer cells. Oncotarget 
8, 111866-111881 (2017). 
20. Tessarz, P., et al. Glutamine methylation in histone H2A is an RNA-polymerase-I-dedicated 
modification. Nature 505, 564-568 (2014). 
 31
21. Goll, M.G., et al. Methylation of tRNAAsp by the DNA methyltransferase homolog Dnmt2. 
Science 311, 395-398 (2006). 
22. Bannister, A.J., Schneider, R. & Kouzarides, T. Histone methylation: dynamic or static? Cell 
109, 801-806 (2002). 
23. Schubeler, D. Function and information content of DNA methylation. Nature 517, 321-326 
(2015). 
24. Maunakea, A.K., Chepelev, I., Cui, K. & Zhao, K. Intragenic DNA methylation modulates 
alternative splicing by recruiting MeCP2 to promote exon recognition. Cell Res 23, 1256-
1269 (2013). 
25. Papin, C., et al. Combinatorial DNA methylation codes at repetitive elements. Genome Res 
27, 934-946 (2017). 
26. Baba, Y., et al. Epigenomic diversity of colorectal cancer indicated by LINE-1 methylation in 
a database of 869 tumors. Mol Cancer 9, 125 (2010). 
27. Howard, G., Eiges, R., Gaudet, F., Jaenisch, R. & Eden, A. Activation and transposition of 
endogenous retroviral elements in hypomethylation induced tumors in mice. Oncogene 27, 
404-408 (2008). 
28. Bannister, A.J. & Kouzarides, T. Regulation of chromatin by histone modifications. Cell Res 
21, 381-395 (2011). 
29. Kolasinska-Zwierz, P., et al. Differential chromatin marking of introns and expressed exons 
by H3K36me3. Nat Genet 41, 376-381 (2009). 
30. Kim, W., Choi, M. & Kim, J.E. The histone methyltransferase Dot1/DOT1L as a critical 
regulator of the cell cycle. Cell Cycle 13, 726-738 (2014). 
31. Wood, K., Tellier, M. & Murphy, S. DOT1L and H3K79 Methylation in Transcription and 
Genomic Stability. Biomolecules 8, 11 (2018). 
32. Garrett-Bakelman, F.E. & Melnick, A.M. Mutant IDH: a targetable driver of leukemic 
phenotypes linking metabolism, epigenetics and transcriptional regulation. Epigenomics 8, 
945-957 (2016). 
33. Bernstein, B.E., et al. A bivalent chromatin structure marks key developmental genes in 
embryonic stem cells. Cell 125, 315-326 (2006). 
34. Jorgensen, S., Schotta, G. & Sorensen, C.S. Histone H4 lysine 20 methylation: key player in 
epigenetic regulation of genomic integrity. Nucleic Acids Res 41, 2797-2806 (2013). 
35. Henikoff, S. & Shilatifard, A. Histone modification: cause or cog? Trends Genet 27, 389-396 
(2011). 
36. Biggar, K.K. & Li, S.S. Non-histone protein methylation as a regulator of cellular signalling 
and function. Nat Rev Mol Cell Biol 16, 5-17 (2015). 
37. Popis, M.C., Blanco, S. & Frye, M. Posttranscriptional methylation of transfer and ribosomal 
RNA in stress response pathways, cell differentiation, and cancer. Curr Opin Oncol 28, 65-
71 (2016). 
38. Dominissini, D., et al. Topology of the human and mouse m6A RNA methylomes revealed 
by m6A-seq. Nature 485, 201-206 (2012). 
39. Roundtree, I.A., Evans, M.E., Pan, T. & He, C. Dynamic RNA Modifications in Gene 
Expression Regulation. Cell 169, 1187-1200 (2017). 
40. Patil, D.P., et al. m(6)A RNA methylation promotes XIST-mediated transcriptional 
repression. Nature 537, 369-373 (2016). 
41. Bartke, T., et al. Nucleosome-interacting proteins regulated by DNA and histone 
methylation. Cell 143, 470-484 (2010). 
42. Foster, B.M., et al. Critical Role of the UBL Domain in Stimulating the E3 Ubiquitin Ligase 
Activity of UHRF1 toward Chromatin. Mol Cell 72, 739-752 e739 (2018). 
 32
43. Bell, A.C. & Felsenfeld, G. Methylation of a CTCF-dependent boundary controls imprinted 
expression of the Igf2 gene. Nature 405, 482-485 (2000). 
44. Hashimoto, H., et al. Structural Basis for the Versatile and Methylation-Dependent Binding 
of CTCF to DNA. Mol Cell 66, 711-720 e713 (2017). 
45. Wilson, V.L. & Jones, P.A. DNA methylation decreases in aging but not in immortal cells. 
Science 220, 1055-1057 (1983). 
46. Unnikrishnan, A., et al. Revisiting the genomic hypomethylation hypothesis of aging. Ann N 
Y Acad Sci 1418, 69-79 (2018). 
47. De Cecco, M., et al. Transposable elements become active and mobile in the genomes of 
aging mammalian somatic tissues. Aging (Albany NY) 5, 867-883 (2013). 
48. Belgnaoui, S.M., Gosden, R.G., Semmes, O.J. & Haoudi, A. Human LINE-1 retrotransposon 
induces DNA damage and apoptosis in cancer cells. Cancer Cell Int 6, 13 (2006). 
49. Gasior, S.L., Wakeman, T.P., Xu, B. & Deininger, P.L. The human LINE-1 retrotransposon 
creates DNA double-strand breaks. J Mol Biol 357, 1383-1393 (2006). 
50. Belancio, V.P., Deininger, P.L. & Roy-Engel, A.M. LINE dancing in the human genome: 
transposable elements and disease. Genome Med 1, 97 (2009). 
51. Tan, L., et al. Naked Mole Rat Cells Have a Stable Epigenome that Resists iPSC 
Reprogramming. Stem Cell Reports 9, 1721-1734 (2017). 
52. Beerman, I., et al. Proliferation-dependent alterations of the DNA methylation landscape 
underlie hematopoietic stem cell aging. Cell Stem Cell 12, 413-425 (2013). 
53. Hannum, G., et al. Genome-wide methylation profiles reveal quantitative views of human 
aging rates. Mol Cell 49, 359-367 (2013). 
54. Maegawa, S., et al. Caloric restriction delays age-related methylation drift. Nat Commun 8, 
539 (2017). 
55. Rakyan, V.K., et al. Human aging-associated DNA hypermethylation occurs preferentially at 
bivalent chromatin domains. Genome Res 20, 434-439 (2010). 
56. Teschendorff, A.E., et al. Age-dependent DNA methylation of genes that are suppressed in 
stem cells is a hallmark of cancer. Genome Res 20, 440-446 (2010). 
57. Esteller, M. CpG island hypermethylation and tumor suppressor genes: a booming present, 
a brighter future. Oncogene 21, 5427-5440 (2002). 
58. Field, A.E., et al. DNA Methylation Clocks in Aging: Categories, Causes, and Consequences. 
Mol Cell 71, 882-895 (2018). 
59. Horvath, S. & Raj, K. DNA methylation-based biomarkers and the epigenetic clock theory of 
ageing. Nat Rev Genet 19, 371-384 (2018). 
60. Marioni, R.E., et al. DNA methylation age of blood predicts all-cause mortality in later life. 
Genome Biol 16, 25 (2015). 
61. Steensma, D.P., et al. Clonal hematopoiesis of indeterminate potential and its distinction 
from myelodysplastic syndromes. Blood 126, 9-16 (2015). 
62. Chen, B.H., et al. DNA methylation-based measures of biological age: meta-analysis 
predicting time to death. Aging (Albany NY) 8, 1844-1865 (2016). 
63. Sen, P., Shah, P.P., Nativio, R. & Berger, S.L. Epigenetic Mechanisms of Longevity and Aging. 
Cell 166, 822-839 (2016). 
64. McCauley, B.S. & Dang, W. Histone methylation and aging: lessons learned from model 
systems. Biochim Biophys Acta 1839, 1454-1462 (2014). 
65. Liu, L., et al. Chromatin modifications as determinants of muscle stem cell quiescence and 
chronological aging. Cell Rep 4, 189-204 (2013). 
66. Sun, D., et al. Epigenomic profiling of young and aged HSCs reveals concerted changes 
during aging that reinforce self-renewal. Cell Stem Cell 14, 673-688 (2014). 
 33
67. Buschbeck, M., et al. The histone variant macroH2A is an epigenetic regulator of key 
developmental genes. Nat Struct Mol Biol 16, 1074-1079 (2009). 
68. Herbig, U., Ferreira, M., Condel, L., Carey, D. & Sedivy, J.M. Cellular senescence in aging 
primates. Science 311, 1257 (2006). 
69. Kreiling, J.A., et al. Age-associated increase in heterochromatic marks in murine and 
primate tissues. Aging Cell 10, 292-304 (2011). 
70. Dang, W., et al. Histone H4 lysine 16 acetylation regulates cellular lifespan. Nature 459, 
802-807 (2009). 
71. O'Sullivan, R.J., Kubicek, S., Schreiber, S.L. & Karlseder, J. Reduced histone biosynthesis and 
chromatin changes arising from a damage signal at telomeres. Nat Struct Mol Biol 17, 
1218-1225 (2010). 
72. Min, K.W., et al. Profiling of m6A RNA modifications identified an age-associated regulation 
of AGO2 mRNA stability. Aging Cell 17, e12753 (2018). 
73. Belancio, V.P., Roy-Engel, A.M., Pochampally, R.R. & Deininger, P. Somatic expression of 
LINE-1 elements in human tissues. Nucleic Acids Res 38, 3909-3922 (2010). 
74. Berman, B.P., et al. Regions of focal DNA hypermethylation and long-range 
hypomethylation in colorectal cancer coincide with nuclear lamina-associated domains. 
Nat Genet 44, 40-46 (2011). 
75. Hansen, K.D., et al. Increased methylation variation in epigenetic domains across cancer 
types. Nat Genet 43, 768-775 (2011). 
76. Genovese, G., et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA 
sequence. N Engl J Med 371, 2477-2487 (2014). 
77. Jaiswal, S., et al. Age-related clonal hematopoiesis associated with adverse outcomes. N 
Engl J Med 371, 2488-2498 (2014). 
78. Xie, M., et al. Age-related mutations associated with clonal hematopoietic expansion and 
malignancies. Nat Med 20, 1472-1478 (2014). 
79. Buscarlet, M., et al. Lineage restriction analyses in CHIP indicate myeloid bias for TET2 and 
multipotent stem cell origin for DNMT3A. Blood 132, 277-280 (2018). 
80. Challen, G.A., et al. Dnmt3a is essential for hematopoietic stem cell differentiation. Nat 
Genet 44, 23-31 (2011). 
81. Jeong, M., et al. Loss of Dnmt3a Immortalizes Hematopoietic Stem Cells In Vivo. Cell Rep 
23, 1-10 (2018). 
82. Ko, M., et al. Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and 
differentiation of hematopoietic stem cells in mice. Proc Natl Acad Sci U S A 108, 14566-
14571 (2011). 
83. Li, Z., et al. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and 
subsequent development of myeloid malignancies. Blood 118, 4509-4518 (2011). 
84. Moran-Crusio, K., et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal 
and myeloid transformation. Cancer Cell 20, 11-24 (2011). 
85. Quivoron, C., et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in 
mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 20, 25-38 
(2011). 
86. Coombs, C.C., et al. Therapy-Related Clonal Hematopoiesis in Patients with Non-
hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes. Cell Stem 
Cell 21, 374-382 e374 (2017). 
87. Fuster, J.J., et al. Clonal hematopoiesis associated with TET2 deficiency accelerates 
atherosclerosis development in mice. Science 355, 842-847 (2017). 
88. Jaiswal, S., et al. Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease. 
N Engl J Med 377, 111-121 (2017). 
 34
89. You, J.S. & Jones, P.A. Cancer genetics and epigenetics: two sides of the same coin? Cancer 
Cell 22, 9-20 (2012). 
90. Elkashef, S.M., et al. IDH Mutation, Competitive Inhibition of FTO, and RNA Methylation. 
Cancer Cell 31, 619-620 (2017). 
91. Flavahan, W.A., et al. Insulator dysfunction and oncogene activation in IDH mutant 
gliomas. Nature 529, 110-114 (2016). 
92. Xu, W., et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-
ketoglutarate-dependent dioxygenases. Cancer Cell 19, 17-30 (2011). 
93. Dang, L., et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 465, 
966 (2010). 
94. Cairns, R.A. & Mak, T.W. Oncogenic isocitrate dehydrogenase mutations: mechanisms, 
models, and clinical opportunities. Cancer Discov 3, 730-741 (2013). 
95. Figueroa, M.E., et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation 
phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 
18, 553-567 (2010). 
96. Glass, J.L., et al. Epigenetic Identity in AML Depends on Disruption of Nonpromoter 
Regulatory Elements and Is Affected by Antagonistic Effects of Mutations in Epigenetic 
Modifiers. Cancer Discov 7, 868-883 (2017). 
97. Gaidzik, V.I., et al. TET2 mutations in acute myeloid leukemia (AML): results from a 
comprehensive genetic and clinical analysis of the AML study group. J Clin Oncol 30, 1350-
1357 (2012). 
98. Su, R., et al. R-2HG Exhibits Anti-tumor Activity by Targeting FTO/m(6)A/MYC/CEBPA 
Signaling. Cell 172, 90-105 e123 (2018). 
99. Piunti, A. & Shilatifard, A. Epigenetic balance of gene expression by Polycomb and 
COMPASS families. Science 352, aad9780 (2016). 
100. Mohammad, F. & Helin, K. Oncohistones: drivers of pediatric cancers. Genes Dev 31, 2313-
2324 (2017). 
101. Schwartzentruber, J., et al. Driver mutations in histone H3.3 and chromatin remodelling 
genes in paediatric glioblastoma. Nature 482, 226-231 (2012). 
102. Sturm, D., et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and 
biological subgroups of glioblastoma. Cancer Cell 22, 425-437 (2012). 
103. Wu, G., et al. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas 
and non-brainstem glioblastomas. Nat Genet 44, 251-253 (2012). 
104. Wan, Y.C.E., Liu, J. & Chan, K.M. Histone H3 Mutations in Cancer. Curr Pharmacol Rep 4, 
292-300 (2018). 
105. Nikbakht, H., et al. Spatial and temporal homogeneity of driver mutations in diffuse 
intrinsic pontine glioma. Nat Commun 7, 11185 (2016). 
106. Mackay, A., et al. Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and 
Diffuse Intrinsic Pontine Glioma. Cancer Cell 32, 520-537 e525 (2017). 
107. Lewis, P.W., et al. Inhibition of PRC2 activity by a gain-of-function H3 mutation found in 
pediatric glioblastoma. Science 340, 857-861 (2013). 
108. Bender, S., et al. Reduced H3K27me3 and DNA hypomethylation are major drivers of gene 
expression in K27M mutant pediatric high-grade gliomas. Cancer Cell 24, 660-672 (2013). 
109. Chan, K.M., et al. The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 
methylation and gene expression. Genes Dev 27, 985-990 (2013). 
110. Justin, N., et al. Structural basis of oncogenic histone H3K27M inhibition of human 
polycomb repressive complex 2. Nat Commun 7, 11316 (2016). 
111. Herz, H.M., et al. Histone H3 lysine-to-methionine mutants as a paradigm to study 
chromatin signaling. Science 345, 1065-1070 (2014). 
 35
112. Wang, X., et al. Molecular analysis of PRC2 recruitment to DNA in chromatin and its 
inhibition by RNA. Nat Struct Mol Biol 24, 1028-1038 (2017). 
113. Stafford, J.M., et al. Multiple modes of PRC2 inhibition elicit global chromatin alterations in 
H3K27M pediatric glioma. Sci Adv 4, eaau5935 (2018). 
114. Castel, D., et al. Histone H3F3A and HIST1H3B K27M mutations define two subgroups of 
diffuse intrinsic pontine gliomas with different prognosis and phenotypes. Acta 
Neuropathol 130, 815-827 (2015). 
115. Grasso, C.S., et al. Functionally defined therapeutic targets in diffuse intrinsic pontine 
glioma. Nat Med 21, 555-559 (2015). 
116. Hashizume, R., et al. Pharmacologic inhibition of histone demethylation as a therapy for 
pediatric brainstem glioma. Nat Med 20, 1394-1396 (2014). 
117. Kruidenier, L., et al. A selective jumonji H3K27 demethylase inhibitor modulates the 
proinflammatory macrophage response. Nature 488, 404-408 (2012). 
118. Mohammad, F., et al. EZH2 is a potential therapeutic target for H3K27M-mutant pediatric 
gliomas. Nat Med 23, 483-492 (2017). 
119. Piunti, A., et al. Therapeutic targeting of polycomb and BET bromodomain proteins in 
diffuse intrinsic pontine gliomas. Nat Med 23, 493-500 (2017). 
120. Dawson, M.A. The cancer epigenome: Concepts, challenges, and therapeutic opportunities. 
Science 355, 1147-1152 (2017). 
121. Pleyer, L. & Greil, R. Digging deep into "dirty" drugs - modulation of the methylation 
machinery. Drug Metab Rev 47, 252-279 (2015). 
122. Dombret, H., et al. International phase 3 study of azacitidine vs conventional care regimens 
in older patients with newly diagnosed AML with >30% blasts. Blood 126, 291-299 (2015). 
123. Fenaux, P., et al. Azacitidine prolongs overall survival compared with conventional care 
regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J 
Clin Oncol 28, 562-569 (2010). 
124. Fenaux, P., et al. Efficacy of azacitidine compared with that of conventional care regimens 
in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, 
phase III study. Lancet Oncol 10, 223-232 (2009). 
125. Silverman, L.R., et al. Randomized controlled trial of azacitidine in patients with the 
myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 20, 
2429-2440 (2002). 
126. Jones, P.A., Issa, J.P. & Baylin, S. Targeting the cancer epigenome for therapy. Nat Rev 
Genet 17, 630-641 (2016). 
127. Oki, Y., Jelinek, J., Shen, L., Kantarjian, H.M. & Issa, J.P. Induction of hypomethylation and 
molecular response after decitabine therapy in patients with chronic myelomonocytic 
leukemia. Blood 111, 2382-2384 (2008). 
128. Tsai, H.C., et al. Transient low doses of DNA-demethylating agents exert durable antitumor 
effects on hematological and epithelial tumor cells. Cancer Cell 21, 430-446 (2012). 
129. Agrawal, K., Das, V., Vyas, P. & Hajduch, M. Nucleosidic DNA demethylating epigenetic 
drugs - A comprehensive review from discovery to clinic. Pharmacol Ther 188, 45-79 
(2018). 
130. Pappalardi, M.B., et al. Abstract 2994: Discovery of selective, noncovalent small molecule 
inhibitors of DNMT1 as an alternative to traditional DNA hypomethylating agents. Cancer 
Research 78, 2994-2994 (2018). 
131. Arrowsmith, C.H., Bountra, C., Fish, P.V., Lee, K. & Schapira, M. Epigenetic protein families: 
a new frontier for drug discovery. Nat Rev Drug Discov 11, 384-400 (2012). 
132. McCabe, M.T., Mohammad, H.P., Barbash, O. & Kruger, R.G. Targeting Histone Methylation 
in Cancer. Cancer J 23, 292-301 (2017). 
 36
133. Margueron, R. & Reinberg, D. The Polycomb complex PRC2 and its mark in life. Nature 469, 
343-349 (2011). 
134. Wassef, M. & Margueron, R. The Multiple Facets of PRC2 Alterations in Cancers. J Mol Biol 
429, 1978-1993 (2017). 
135. Beguelin, W., et al. EZH2 is required for germinal center formation and somatic EZH2 
mutations promote lymphoid transformation. Cancer Cell 23, 677-692 (2013). 
136. Morin, R.D., et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-
cell lymphomas of germinal-center origin. Nat Genet 42, 181-185 (2010). 
137. Sneeringer, C.J., et al. Coordinated activities of wild-type plus mutant EZH2 drive tumor-
associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell 
lymphomas. Proc Natl Acad Sci U S A 107, 20980-20985 (2010). 
138. Bodor, C., et al. EZH2 mutations are frequent and represent an early event in follicular 
lymphoma. Blood 122, 3165-3168 (2013). 
139. LaFave, L.M., et al. Loss of BAP1 function leads to EZH2-dependent transformation. Nat 
Med 21, 1344-1349 (2015). 
140. Kim, K.H., et al. SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of 
EZH2. Nat Med 21, 1491-1496 (2015). 
141. Bitler, B.G., et al. Synthetic lethality by targeting EZH2 methyltransferase activity in 
ARID1A-mutated cancers. Nat Med 21, 231-238 (2015). 
142. Wilson, B.G., et al. Epigenetic antagonism between polycomb and SWI/SNF complexes 
during oncogenic transformation. Cancer Cell 18, 316-328 (2010). 
143. Stanton, B.Z., et al. Smarca4 ATPase mutations disrupt direct eviction of PRC1 from 
chromatin. Nat Genet 49, 282-288 (2017). 
144. Kadoch, C., et al. Dynamics of BAF-Polycomb complex opposition on heterochromatin in 
normal and oncogenic states. Nat Genet 49, 213-222 (2017). 
145. Bitler, B.G., Aird, K.M. & Zhang, R. Epigenetic synthetic lethality in ovarian clear cell 
carcinoma: EZH2 and ARID1A mutations. Mol Cell Oncol 3, e1032476 (2016). 
146. Campagne, A., et al. BAP1 complex promotes transcription by opposing PRC1-mediated 
H2A ubiquitylation. Nat Commun 10, 348 (2019). 
147. Schoumacher, M., et al. Uveal melanoma cells are resistant to EZH2 inhibition regardless of 
BAP1 status. Nat Med 22, 577-578 (2016). 
148. Ernst, T., et al. Inactivating mutations of the histone methyltransferase gene EZH2 in 
myeloid disorders. Nat Genet 42, 722-726 (2010). 
149. Puda, A., et al. Frequent deletions of JARID2 in leukemic transformation of chronic myeloid 
malignancies. Am J Hematol 87, 245-250 (2012). 
150. Score, J., et al. Inactivation of polycomb repressive complex 2 components in 
myeloproliferative and myelodysplastic/myeloproliferative neoplasms. Blood 119, 1208-
1213 (2012). 
151. Ueda, T., et al. EED mutants impair polycomb repressive complex 2 in myelodysplastic 
syndrome and related neoplasms. Leukemia 26, 2557-2560 (2012). 
152. Nikoloski, G., van der Reijden, B.A. & Jansen, J.H. Mutations in epigenetic regulators in 
myelodysplastic syndromes. Int J Hematol 95, 8-16 (2012). 
153. Lee, W., et al. PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant 
peripheral nerve sheath tumors. Nat Genet 46, 1227-1232 (2014). 
154. Ntziachristos, P., et al. Genetic inactivation of the polycomb repressive complex 2 in T cell 
acute lymphoblastic leukemia. Nat Med 18, 298-301 (2012). 
155. Zhang, J., et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. 
Nature 481, 157-163 (2012). 
 37
156. Comet, I., Riising, E.M., Leblanc, B. & Helin, K. Maintaining cell identity: PRC2-mediated 
regulation of transcription and cancer. Nat Rev Cancer 16, 803-810 (2016). 
157. Chen, L., et al. CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency 
on EZH2. J Clin Invest 128, 446-462 (2018). 
158. Tsubota, S., et al. PRC2-Mediated Transcriptomic Alterations at the Embryonic Stage 
Govern Tumorigenesis and Clinical Outcome in MYCN-Driven Neuroblastoma. Cancer Res 
77, 5259-5271 (2017). 
159. Iliopoulos, D., et al. Loss of miR-200 inhibition of Suz12 leads to polycomb-mediated 
repression required for the formation and maintenance of cancer stem cells. Mol Cell 39, 
761-772 (2010). 
160. Gardner, E.E., et al. Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an 
EZH2-SLFN11 Axis. Cancer Cell 31, 286-299 (2017). 
161. Hubaux, R., et al. EZH2 promotes E2F-driven SCLC tumorigenesis through modulation of 
apoptosis and cell-cycle regulation. J Thorac Oncol 8, 1102-1106 (2013). 
162. Kleer, C.G., et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic 
transformation of breast epithelial cells. Proc Natl Acad Sci U S A 100, 11606-11611 (2003). 
163. Varambally, S., et al. The polycomb group protein EZH2 is involved in progression of 
prostate cancer. Nature 419, 624-629 (2002). 
164. N. Chi, S., et al. A phase I study of the EZH2 inhibitor tazemetostat in pediatric subjects with 
relapsed or refractory INI1-negative tumors or synovial sarcoma, (2016). 
165. Zauderer, M.G., et al. Phase 2, multicenter study of the EZH2 inhibitor tazemetostat as 
monotherapy in adults with relapsed or refractory (R/R) malignant mesothelioma (MM) 
with BAP1 inactivation. Journal of Clinical Oncology 36, 8515-8515 (2018). 
166. Positive Results for Tazemetostat in Follicular Lymphoma. Cancer Discovery 8, OF3-OF3 
(2018). 
167. McCabe, M.T., et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-
activating mutations. Nature 492, 108-112 (2012). 
168. Knutson, S.K., et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant 
lymphoma cells. Nat Chem Biol 8, 890-896 (2012). 
169. Souroullas, G.P., et al. An oncogenic Ezh2 mutation induces tumors through global 
redistribution of histone 3 lysine 27 trimethylation. Nat Med 22, 632-640 (2016). 
170. Stein, E.M., et al. The DOT1L inhibitor pinometostat reduces H3K79 methylation and has 
modest clinical activity in adult acute leukemia. Blood 131, 2661-2669 (2018). 
171. Gulla, A., et al. Protein arginine methyltransferase 5 has prognostic relevance and is a 
druggable target in multiple myeloma. Leukemia 32, 996-1002 (2018). 
172. Blanc, R.S. & Richard, S. Arginine Methylation: The Coming of Age. Mol Cell 65, 8-24 (2017). 
173. Hu, D., et al. Interplay between arginine methylation and ubiquitylation regulates KLF4-
mediated genome stability and carcinogenesis. Nat Commun 6, 8419 (2015). 
174. Tarighat, S.S., et al. The dual epigenetic role of PRMT5 in acute myeloid leukemia: gene 
activation and repression via histone arginine methylation. Leukemia 30, 789-799 (2016). 
175. Yan, F., et al. Genetic validation of the protein arginine methyltransferase PRMT5 as a 
candidate therapeutic target in glioblastoma. Cancer Res 74, 1752-1765 (2014). 
176. Koh, C.M., et al. MYC regulates the core pre-mRNA splicing machinery as an essential step 
in lymphomagenesis. Nature 523, 96-100 (2015). 
177. Li, Y., et al. PRMT5 is required for lymphomagenesis triggered by multiple oncogenic 
drivers. Cancer Discov 5, 288-303 (2015). 
178. Mack, S.C., et al. Epigenomic alterations define lethal CIMP-positive ependymomas of 
infancy. Nature 506, 445-450 (2014). 
 38
179. Chan-Penebre, E., et al. A selective inhibitor of PRMT5 with in vivo and in vitro potency in 
MCL models. Nat Chem Biol 11, 432-437 (2015). 
180. Klose, R.J., Kallin, E.M. & Zhang, Y. JmjC-domain-containing proteins and histone 
demethylation. Nat Rev Genet 7, 715-727 (2006). 
181. Somervaille, T., et al. Safety, Phamacokinetics (PK), Pharmacodynamics (PD) and 
Preliminary Activity in Acute Leukemia of Ory-1001, a First-in-Class Inhibitor of Lysine-
Specific Histone Demethylase 1A (LSD1/KDM1A): Initial Results from a First-in-Human 
Phase 1 Study. Blood 128, 4060-4060 (2016). 
182. Hamamoto, R., Saloura, V. & Nakamura, Y. Critical roles of non-histone protein lysine 
methylation in human tumorigenesis. Nature Reviews Cancer 15, 110 (2015). 
183. Biggar, K.K. & Li, S.S.C. Non-histone protein methylation as a regulator of cellular signalling 
and function. Nature Reviews Molecular Cell Biology 16, 5 (2014). 
184. Fong, C.Y., et al. BET inhibitor resistance emerges from leukaemia stem cells. Nature 525, 
538-542 (2015). 
185. Rathert, P., et al. Transcriptional plasticity promotes primary and acquired resistance to 
BET inhibition. Nature 525, 543-547 (2015). 
186. Shu, S., et al. Response and resistance to BET bromodomain inhibitors in triple-negative 
breast cancer. Nature 529, 413-417 (2016). 
187. Tyler, D.S., et al. Click chemistry enables preclinical evaluation of targeted epigenetic 
therapies. Science 356, 1397-1401 (2017). 
188. Holohan, C., Van Schaeybroeck, S., Longley, D.B. & Johnston, P.G. Cancer drug resistance: 
an evolving paradigm. Nat Rev Cancer 13, 714-726 (2013). 
189. Marazzi, I., Greenbaum, B.D., Low, D.H.P. & Guccione, E. Chromatin dependencies in 
cancer and inflammation. Nat Rev Mol Cell Biol 19, 245-261 (2018). 
190. Sigalotti, L., Fratta, E., Coral, S. & Maio, M. Epigenetic drugs as immunomodulators for 
combination therapies in solid tumors. Pharmacol Ther 142, 339-350 (2014). 
191. Chiappinelli, K.B., et al. Inhibiting DNA Methylation Causes an Interferon Response in 
Cancer via dsRNA Including Endogenous Retroviruses. Cell 162, 974-986 (2015). 
192. Roulois, D., et al. DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing 
Viral Mimicry by Endogenous Transcripts. Cell 162, 961-973 (2015). 
193. Sheng, W., et al. LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint 
Blockade. Cell 174, 549-563 e519 (2018). 
194. Topper, M.J., et al. Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion 
and Treating Lung Cancer. Cell 171, 1284-1300 e1221 (2017). 
195. Stone, M.L., et al. Epigenetic therapy activates type I interferon signaling in murine ovarian 
cancer to reduce immunosuppression and tumor burden. Proc Natl Acad Sci U S A 114, 
E10981-E10990 (2017). 
196. Arenas-Ramirez, N., Sahin, D. & Boyman, O. Epigenetic mechanisms of tumor resistance to 
immunotherapy. Cell Mol Life Sci 75, 4163-4176 (2018). 
197. Han, D., et al. Anti-tumour immunity controlled through mRNA m(6)A methylation and 
YTHDF1 in dendritic cells. Nature 566, 270-274 (2019). 
198. Brach, D., et al. EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell 
Activation Signaling in DLBCL. Mol Cancer Ther 16, 2586-2597 (2017). 
199. Beguelin, W., et al. EZH2 and BCL6 Cooperate to Assemble CBX8-BCOR Complex to Repress 
Bivalent Promoters, Mediate Germinal Center Formation and Lymphomagenesis. Cancer 
Cell 30, 197-213 (2016). 
200. Matei, D., et al. Epigenetic resensitization to platinum in ovarian cancer. Cancer Res 72, 
2197-2205 (2012). 
 39
201. Nguyen, A.T. & Zhang, Y. The diverse functions of Dot1 and H3K79 methylation. Genes Dev 
25, 1345-1358 (2011). 
202. Huyen, Y., et al. Methylated lysine 79 of histone H3 targets 53BP1 to DNA double-strand 
breaks. Nature 432, 406-411 (2004). 
203. Lin, Y.H., et al. Global reduction of the epigenetic H3K79 methylation mark and increased 
chromosomal instability in CALM-AF10-positive leukemias. Blood 114, 651-658 (2009). 
204. Wakeman, T.P., Wang, Q., Feng, J. & Wang, X.F. Bat3 facilitates H3K79 dimethylation by 
DOT1L and promotes DNA damage-induced 53BP1 foci at G1/G2 cell-cycle phases. EMBO J 
31, 2169-2181 (2012). 
205. Oksenych, V., et al. Histone methyltransferase DOT1L drives recovery of gene expression 
after a genotoxic attack. PLoS Genet 9, e1003611 (2013). 
206. Prebet, T., et al. Prolonged administration of azacitidine with or without entinostat for 
myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related 
changes: results of the US Leukemia Intergroup trial E1905. J Clin Oncol 32, 1242-1248 
(2014). 
207. Kalin, J.H., et al. Targeting the CoREST complex with dual histone deacetylase and 
demethylase inhibitors. Nat Commun 9, 53 (2018). 
208. Liu, X.S., et al. Editing DNA Methylation in the Mammalian Genome. Cell 167, 233-247 e217 
(2016). 
209. Liszczak, G.P., et al. Genomic targeting of epigenetic probes using a chemically tailored 
Cas9 system. Proceedings of the National Academy of Sciences 114, 681-686 (2017). 
210. Luskin, M.R., et al. A clinical measure of DNA methylation predicts outcome in de novo 
acute myeloid leukemia. JCI Insight 1(2016). 
211. Koch, A., et al. Analysis of DNA methylation in cancer: location revisited. Nat Rev Clin Oncol 
15, 459-466 (2018). 
212. Bienkowski, M., et al. Clinical Neuropathology practice guide 5-2015: MGMT methylation 
pyrosequencing in glioblastoma: unresolved issues and open questions. Clin Neuropathol 
34, 250-257 (2015). 
213. Shen, S.Y., et al. Sensitive tumour detection and classification using plasma cell-free DNA 
methylomes. Nature 563, 579-583 (2018). 
214. Dawson, S.J., et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. 
N Engl J Med 368, 1199-1209 (2013). 
215. Agarwal, R., et al. Dynamic molecular monitoring reveals that SWI-SNF mutations mediate 
resistance to ibrutinib plus venetoclax in mantle cell lymphoma. Nat Med (2018). 
216. Rodriguez-Terrones, D. & Torres-Padilla, M.E. Nimble and Ready to Mingle: Transposon 
Outbursts of Early Development. Trends Genet 34, 806-820 (2018). 
217. Faulkner, G.J., et al. The regulated retrotransposon transcriptome of mammalian cells. 
Nature Genetics 41, 563 (2009). 
218. Tchasovnikarova, I.A., et al. GENE SILENCING. Epigenetic silencing by the HUSH complex 
mediates position-effect variegation in human cells. Science 348, 1481-1485 (2015). 
219. Liu, N., et al. Selective silencing of euchromatic L1s revealed by genome-wide screens for 
L1 regulators. Nature 553, 228-232 (2018). 
220. Stadler, M.B., et al. DNA-binding factors shape the mouse methylome at distal regulatory 
regions. Nature 480, 490-495 (2011). 
221. Ohm, J.E., et al. A stem cell-like chromatin pattern may predispose tumor suppressor genes 
to DNA hypermethylation and heritable silencing. Nat Genet 39, 237-242 (2007). 
222. Schlesinger, Y., et al. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks 
genes for de novo methylation in cancer. Nat Genet 39, 232-236 (2007). 
 40
223. Widschwendter, M., et al. Epigenetic stem cell signature in cancer. Nat Genet 39, 157-158 
(2007). 
224. Qiu, L., et al. Mechanism of cancer: Oncohistones in action. J Genet Genomics 45, 227-236 
(2018). 
225. Fang, J., et al. Cancer-driving H3G34V/R/D mutations block H3K36 methylation and 
H3K36me3-MutSalpha interaction. Proc Natl Acad Sci U S A 115, 9598-9603 (2018). 
226. Canadas, I., et al. Tumor innate immunity primed by specific interferon-stimulated 
endogenous retroviruses. Nat Med 24, 1143-1150 (2018). 
227. Zingg, D., et al. The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive 
Resistance to Tumor Immunotherapy. Cell Rep 20, 854-867 (2017). 
228. Abou El Hassan, M., et al. Cancer Cells Hijack PRC2 to Modify Multiple Cytokine Pathways. 
PLoS One 10, e0126466 (2015). 
229. Peng, D., et al. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and 
immunotherapy. Nature 527, 249-253 (2015). 
230. Wang, D., et al. Targeting EZH2 Reprograms Intratumoral Regulatory T Cells to Enhance 
Cancer Immunity. Cell Rep 23, 3262-3274 (2018). 
231. Goswami, S., et al. Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-
4 therapy. J Clin Invest 128, 3813-3818 (2018). 
 
5’
me
C G
me
DNMT1
DNMT3A
DNMT3B
G C
C G
5’
G C
me
DNMT3A
DNMT3B
TET/TDG
A
me
?
N
ON
H C3
NH2
R
N
ON
NH2
R
cytosine (C) 5-methylcytosine
                     (5mC)
N
N
NH2
X
N
N
N
N
HN
X
N
N
CH3
adenosine (A) N -methyladenosine (m6A)6
(R = deoxyribose)
N
ON
NH2
R
HO
5-hydoxymethylcytosine
                                  (5hmC)
N
ON
HC
NH2
R
O
N
ON
C
NH2
R
O
HO
5-formylcytosine (5fC)
H C2
5-carboxylcytosine (5caC)
O
A TRMT10C (m1A)METTL3/METTL14 (m6A)
METTL16 (m6A)
DIMT1 (m6,6A)
FBL, TRMT13 (Am)
FTO (m6A)
G
TRMT10A/B/C,
TRMT5 (m1G)
TGS1 (m2,7G)
TRMT1 (m2,2G)
METTL1,RNMT 
WBSCR22,  (m7G)
MRM1, RNMTL1,
FBL (Gm)
C
DNMT2 (m5C)
NSUN1-7 (m5C)
FBL, TRMT13, FTSJ1 (Cm)
U
MRM2, FBL, FTSJ3 (Um)
DNMT
TET
TET
TET
TDG/
    BER TDG
TDG: Thymine DNA glycosylase    BER: Base excision repair
NH2
NH
N
N
N
O
NH2
NH
N
N
N
H C3
X X
guanosine (G) N -methylguanosine (m7G)7
N
N
NH2
N
N
O
OH OH
S
H C3
+
N3H
OH
O
N
N
NH2
N
N
O
OH OH
S
N3H
OH
O
       S-adenosyl methionine (SAM)        S-adenosyl homocysteine (SAH)
       Unmethylated substrate                                         Methylated substrate
TET/TDG
DNA (X = deoxyribose)RNA
Methylation reaction
METTL3/14
METTL16
FTO 
A     R     T      K     Q     T     A     R     K     S     .......   P     R     K    ......    R    K    S    A    P    ......   V    K    K    P ..... K .... K ...... 
me
MLL1-4
SET1A
SET1B
ASH1L
SET7/9
PRDM9
SMYD 1, 2 & 3
SUV39H1/H2
G9a
GLP
ESET/SETDB1
PRDM family
Pme
CARM1
PRMT6
me me me me me
PRMT5 CARM1 CARM1
EZH1
EZH2
2                     4                                            8        9                                                17                                 26     27                                                             36                               56         79
me
SET2
NSD1-3
SMYD2
ASH1L
SETD2 & 3
SETMAR
JHDM1 family
JHDM3 family
me
DOT1L
me Methylation
UTX
UTY
JMJD3
PHF8
H3
S      G      R      G      K      G      G      ........     R      K      V       L      R ...... H4
                                             3                       5                                                                        20  
me
PRMT1, 3 & 5
me
SET8
SMYD5
SUV4-20H1/H2
JMJD6 LSD1
LSD2
NO66
JARID1A-D
JHDM1
LSD1
JHDM2 family
JHDM3 family
PHF8
G9a
me
JMJD6
me
SMYD5
PHF8
PHF2
Methyltransferases above
Demethylases below
Histones
H
H
N
H
lysine (K) ε-N-monomethyllysine
(Kme1)
H
H
ε-N-dimethyllysine
(Kme2)
ε-N-trimethyllysine
(Kme3)
H3C
(CH2)4 (CH2)4
N
HH3C
H3C (CH2)4
N
H3C
H3C (CH2)4
N
CH3++ +
H
N C
H 
C 
O H
N C
H 
C 
O H
N C
H 
C 
O H
N C
H 
C 
O 
KMT KMTKMT
KDM KDM KDM 
+
+
(CH2)3
NH
C
NH2N
CH3
H
(CH2)3
NH
C
N
H
N
CH3
H
(CH2)3
NH
C
NH2N
CH3
PRMT
ω-N -monomethylarginine
(Rme1)
       asymmetric
+
+
CH3
       symmetric
PRMT
(CH2)3
NH
C
NH2H2N
arginine (R)
+
CH3
G
GG
Type I
Type I & II
PRMT
Type II
H
N C
H 
C 
O H
N C
H 
C 
O 
H
N C
H 
C 
O 
H
N C
H 
C 
O 
RDM 
RDM 
RDM 
ω-N ,N’ -dimethylarginine
         (Rme2s)
GG
ω-N ,N -dimethylarginine
               (Rme2as)
Lysine
Arginine
METTL1
? 
A
B C
D
m6A
m7G
E
a. b.
HP1 HP1
c. d.
HP1 HP1
Nucleosome Nucleosome
with macro H2A
HP1
HP1β repressive
marks
H3K4me3
H3K27me3
unmethylated CpG
5mC
CTCF
cohesin
enhancer
gene 
repeat region
5hmC
gene 
TSG 
TSG 
TSG 
promoter
intergenic region
TSG 
TSG 
TSG 
H3.3K27M H3.3G34RH3.1K27M
IDH1
IDH2
isocitrate
a-KG
D2HG
IDH1
IDH2
R132
R140/R172
TET2
JMJC
FTO
5hmC
5mC
HK
HKme
m6A
m6Ame
DNA methylation
Histone methylation
Hypermethylated Hypomethylated Hypomethylated
methylation H3K27me2/3 H3K36me3 redistributed
IDH1 IDH2
a. oncometabolites b. oncohistones
PRC2
Active
Inactive
K27
K27M
SETD2
K36
G34
PRC2
SETD2
K36
G34R
Immunotherapy
MHC-I
anti-CTLA-4
anti-PD-1/
anti-PD-L1
NK cell
T reg
DC
anti-CTLA-4
CD8
T cell
Macrophage
IFNAR
EZH2i
DNMTi
dsRNA
Cancer Testis
Antigens
LSD1i
ISGs
IFNGR
EZH2i
CXCL9
CXCL10
Tumour Cell
5mC
5mC
cell free DNA
a. Targeted drug delivery b. Liquid biopsies
Drug
dCas9
sgRNA TF
RNA pol II
5hmC
5hmC
Tumour cell
dying cell
Blood vessel
